EP1268775B1 - Das hohe knochenmasse gen auf 11q13.3 - Google Patents

Das hohe knochenmasse gen auf 11q13.3 Download PDF

Info

Publication number
EP1268775B1
EP1268775B1 EP00941578A EP00941578A EP1268775B1 EP 1268775 B1 EP1268775 B1 EP 1268775B1 EP 00941578 A EP00941578 A EP 00941578A EP 00941578 A EP00941578 A EP 00941578A EP 1268775 B1 EP1268775 B1 EP 1268775B1
Authority
EP
European Patent Office
Prior art keywords
seq
hbm
nucleic acid
dna
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00941578A
Other languages
English (en)
French (fr)
Other versions
EP1268775A1 (de
Inventor
John P. Carulli
Randall D. Little
Robert R. Recker
Mark L. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Oscient Pharmaceuticals Corp
Original Assignee
Creighton University
Oscient Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,771 external-priority patent/US6780609B1/en
Priority claimed from US09/544,398 external-priority patent/US6770461B1/en
Application filed by Creighton University, Oscient Pharmaceuticals Corp filed Critical Creighton University
Priority to EP08006373A priority Critical patent/EP1964921A3/de
Publication of EP1268775A1 publication Critical patent/EP1268775A1/de
Application granted granted Critical
Publication of EP1268775B1 publication Critical patent/EP1268775B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates generally to the field of genetics, genomics and molecular biology. More particularly, the invention relates to methods and materials used to isolate, detect and sequence a high bone mass gene and corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof.
  • the genes identified in the present invention are implicated in the ontology and physiology of bone development.
  • the invention also provides nucleic acids, proteins, cloning vectors, expression vectors, tramformed non-human hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and manufacturing medicaments for treating diseases involved in bone development.
  • the present invention is directed to methods for manufacturing medicamentss for treating, diagnosing, preventing and screening for normal and abnormal conditions of bone, including metabolic bone diseases such as osteoporosis.
  • Osteoporosis affects men as well as women, and, taken with other abnormalities of bone, presents an ever-increasing health risk for an aging population.
  • the most common type of osteoporosis is that associated with menopause. Most women lose between 20-60% of the bone mass in the trabecular compartment of the bone within 3-6 years after the cessation of menses. This rapid loss is generally associated with an increase of bone resorption and formation. However, the resorptive cycle is more dominant and the result is a net loss of bone mass. Osteoporosis is a common and serious disease among postmenopausal women.
  • osteoporosis is generally not thought of as a life-threatening condition, a 20-30% mortality rate is related to hip fractures in elderly women. A large percentage of this mortality rate can be directly associated with postmenopausal osteoporosis.
  • the most vulnerable tissue in the bone to the effects of postmenopausal osteoporosis is the trabecular bone.
  • This tissue is often referred to as spongy bone and is particularly concentrated near the ends of the bone near the joints and in the vertebrae of the spine.
  • the trabecular tissue is characterized by small structures which inter-connect with each other as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This criss-cross network of trabeculae gives lateral support to the outer cortical structure and is critical to the biomechanical strength of the overall structure. In postmenopausal osteoporosis, it is primarily the net resorption and loss of the trabeculae which lead to the failure and fracture of the bone.
  • estrogen replacement therapy One of the earliest generally accepted methods for treatment of postmenopausal osteoporosis was estrogen replacement therapy. Although this therapy frequently is successful, patient compliance is low, primarily due to the undesirable side-effects of chronic estrogen treatment. Frequently cited side-effects of estrogen replacement therapy include reinitiation of menses, bloating, depression, and fear of breast or uterine cancer. In order to limit the known threat of uterine cancer in those women who have not undergone a hysterectomy, a protocol of estrogen and progestin cyclic therapy is often employed. This protocol is similar to that which is used in birth control regimens, and often is not tolerated by women because of the side-effects characteristic of progestin.
  • Calcitonin is a naturally occurring peptide which inhibits bone resorption and has been approved for this use in many countries ( Overgaard et al, Br. Med. J., 305:556-561 (1992 )). The use of calcitonin has been somewhat limited, however. Its effects are very modest in increasing bone mineral density and the treatment is very expensive.
  • Another therapy for the treatment of postmenopausal osteoporosis is the use of bis-phosphonates. These compounds were originally developed for use in Paget's disease and malignant hypercalcemia. They have been shown to inhibit bone resorption.
  • Alendronate one compound of this class, has been approved for the treatment of postmenopausal osteoporosis. These agents may be helpful in the treatment of osteoporosis, but these agents also have potential liabilities which include osteomalacia, extremely long half-life in bone (greater than 2 years), and possible "frozen bone syndrome,” e.g., the cessation of normal bone remodeling.
  • Senile osteoporosis is similar to postmenopausal osteoporosis in that it is marked by the loss of bone mineral density and resulting increase in fracture rate, morbidity, and associated mortality. Generally, it occurs in later life, i.e., after 70 years of age. Historically, senile osteoporosis has been more common in females, but with the advent of a more elderly male population, this disease is becoming a major factor in the health of both sexes. It is not clear what, if any, role hormones such as testosterone or estrogen have in this disease, and its etiology remains obscure. Treatment of this disease has not been very satisfactory. Hormone therapy, estrogen in women and testosterone in men, has shown equivocal results; calcitonin and bis-phosphonates may be of some utility.
  • Peak skeletal mass is the most powerful determinant of bone mass in elderly years ( Hui et al, Ann. Int. Med., 111:355-361 (1989 )), even though the rate of age-related bone loss in adult and later life is also a strong determinant ( Hui et al, Osteoporosis Int., 1:30-34 (1995 )). Since bone mass is the principal measurable determinant of fracture risk, the inherited peak skeletal mass achieved at maturity is an important determinant of an individual's risk of fracture later in life. Thus, study of the genetic basis of bone mass is of considerable interest in the etiology of fractures due to osteoporosis.
  • linkage analysis can be used to find the location of a gene causing a hereditary "disorder" and does not require any knowledge of the biochemical nature of the disorder, i.e., a mutated protein that is believed to cause the disorder does not need to be known.
  • Traditional approaches depend on assumptions concerning the disease process that might implicate a known protein as a candidate to be evaluated.
  • the genetic localization approach using linkage analysis can be used to first find the general chromosomal region in which the defective gene is located and then to gradually reduce the size of the region in order to determine the location of the specific mutated gene as precisely as possible. After the gene itself is discovered within the candidate region, the messenger RNA and the protein are identified and, along with the DNA, are checked for mutations.
  • HBM high bone mass
  • Linkage analysis is possible because of the nature of inheritance of chromosomes from parents to offspring.
  • the two parental homologues pair to guide their proper separation to daughter cells. While they are lined up and paired, the two homologues exchange pieces of the chromosomes, in an event called "crossing over" or "recombination.”
  • the resulting chromosomes are chimeric, that is, they contain parts that originate from both parental homologues. The closer together two sequences are on the chromosome, the less likely that a recombination event will occur between them, and the more closely linked they are.
  • two positions on the chromosomes are followed from one generation to the next to determine the frequency of recombination between them.
  • one of the chromosomal positions is marked by the disease gene or its normal counterpart, i.e., the inheritance of the chromosomal region can be determined by examining whether the individual displays symptoms of the disorder or not.
  • the other position is marked by a DNA sequence that shows natural variation in the population such that the two homologues can be distinguished based on the copy of the "marker" sequence that they possess.
  • the inheritance of the genetic marker sequence is compared to the inheritance of the disease state.
  • chromosomes may be systematically checked with known markers and compared to the disease state.
  • the data obtained from the different families is combined, and analyzed together by a computer using statistical methods.
  • the result is information indicating the probability of linkage between the genetic marker and the disease allowing different distances between them.
  • a positive result can mean that the disease is very close to the marker, while a negative result indicates that it is far away on that chromosome, or on an entirely different chromosome.
  • Linkage analysis is performed by typing all members of the affected family at a given marker locus and evaluating the co-inheritance of a particular disease state with the marker probe, thereby determining how often the two of them are co-inherited.
  • the recombination frequency can be used as a measure of the genetic distance between two gene loci.
  • a recombination frequency of 1% is equivalent to 1 map unit, or 1 centiMorgan (cM), which is roughly equivalent to 1,000 kb of DNA. This relationship holds up to frequencies of about 20% or 20 cM.
  • the entire human genome is 3,300 cM long. In order to find an unknown disease gene within 5-10 cM of a marker locus, the whole human genome can be searched with roughly 330 informative marker loci spaced at approximately 10 cM intervals ( Botstein et al, Am. J. Hum. Genet., 32:314-331 (1980 )).
  • the reliability of linkage results is established by using a number of statistical methods. The method most commonly used for the analysis of linkage in humans is the LOD score method ( Morton, Prog. Clin. Biol. Res., 147:245-265 (1984 ), Morton et al, Am. J. Hum. Genet., 38:868-883 (1986 )) which was incorporated into the computer program LIPED by Ott, Am.
  • LOD scores are the logarithm of the ratio of the likelihood that two loci are linked at a given distance to that they are not linked (>50 cM apart).
  • the advantage of using logarithmic values is that they can be summed among families with the same disease. This becomes necessary given the relatively small size of human families.
  • Multi-point analysis provide a simultaneous analysis of linkage between the disease and several linked genetic markers, when the recombination distance among the markers is known.
  • Multi-point analysis is advantageous for two reasons.
  • an indication of the position of the disease gene among the markers may be determined. This allows identification of flanking markers, and thus eventually allows isolation of a small region in which the disease gene resides. Lathrop et al, Proc. Natl. Acad. Sci.
  • the present invention is directed to this, as well as other, important ends.
  • the present invention describes the Zmax1 gene and the HBM gene on chromosome 11q13.3 by genetic linkage and mutation analysis.
  • the use of additional genetic markers linked to the genes has aided this discovery.
  • linkage analysis and mutation analysis persons predisposed to HBM may be readily identified.
  • Cloning methods using Bacterial Artificial Chromosomes have enabled the inventors to focus on the chromosome region of 11q13.3 and to accelerate the sequencing of the autosomal dominant gene.
  • the invention identifies the Zmax1 gene and the HBM gene, and identifies the guanine-to-thymine polymorphism mutation at position 582 in the Zmax1 gene that produces the HBM gene and the HBM phenotype.
  • the present invention identifies the Zmax1 gene and the HBM gene, which can be used to determine if people are predisposed to HBM and, therefore, not susceptible to diseases characterized by reduced bone density, including, for example, osteoporosis, or are predisposed and susceptible to diseases characterized by abnormally high bone density, such as, for example, osteoporosis.
  • Older individuals carrying the HBM gene express the HBM protein, and, therefore, do not develop osteoporosis.
  • the HBM gene is a suppressor of osteoporosis. This in vivo observation is a strong evidence that treatment of normal individuals with the HBM gene or protein, or fragments thereof, will ameliorate osteoporosis.
  • Such treatment will be indicated in the treatment of bone lesions, particularly bone fractures, for bone remodeling in the healing of such lesions.
  • persons predisposed to or suffering from stress fractures i.e., the accumulation of stress-induced microfractures, eventually resulting in a true fracture through the bone cortex
  • the medicaments and compositions of the invention will be of use in the treatment of secondary osteoporosis, where the course of therapy involves bone remodeling, such as endocrine conditions accompanying corticosteroid administration, hyperthyroidism, hypogonadism, hematologic malignancies, malabsorption and alcoholism, as well as disorders associated with vitamin D and/or phosphate metabolism, such as osteomalacia and rickets, and diseases characterized by abnormal or disordered bone remodeling, such as Paget's disease, and in neoplasms of bone, which may be benign or malignant.
  • bone remodeling such as endocrine conditions accompanying corticosteroid administration, hyperthyroidism, hypogonadism, hematologic malignancies, malabsorption and alcoholism, as well as disorders associated with vitamin D and/or phosphate metabolism, such as osteomalacia and rickets, and diseases characterized by abnormal or disordered bone remodeling, such as Paget's disease, and in neoplasms
  • the present invention is directed to nucleic acids, proteins, vectors, and transformed non-human hosts of HBM and Zmax 1.
  • the present invention is directed to applications of the above embodiments of the invention including, for example, medicaments for gene therapy, pharmaceutical development, and diagnostic assay for bone development disorders.
  • the present invention is directed to medicaments for treating, diagnosing, preventing and screening for osteoporosis.
  • the present invention provides:
  • the invention provides a method for identification of a candidate molecule involved in bone modulation comprising
  • the present invention also provides an in vitro method of pharmaceutical development for treatment of bone development disorders comprising identifying a molecule that binds to the amino acid sequence of SEQ ID NO: 4.
  • the invention provides an in vitro method of pharmaceutical development for treatment of bone development disorders the method comprising
  • the invention provides:
  • the invention further provides an isolated high bone mass (HBM) polynucleotide comprising a nucleic acid selected from the group consisting of:
  • the invention provides an isolated nucleic acid sequence comprising at least 15 contiguous nucleotides of SEQ ID NO: 2, wherein said 15 contiguous nucleotides comprise nucleotides which encode for an amino acid substitution at position 171 of SEQ ID NO: 4, which substitution is associated with a high bone mass phenotype.
  • the invention also provides an isolated high bone mass (HBM) polynucleotide comprising a nucleic acid selected from the group consisting of:
  • the present invention provides for:
  • Fig. 1 shows the pedigree of the individuals used in the genetic linkage studies. Under each individual is an ID number, the z-score for spinal BMD, and the allele calls for the critical markers on chromosome solid symbols represent"affected"individuals. Symbols containing"N"are"unaffected”individuals. DNA from 37 individuals was genotyped. Question marks denote unknown genotypes or individuals who were not genotyped.
  • Fig. 2 depicts the BAC/STS content physical map of the HBM region in 11q13.3.
  • STS markers derived from genes, ESTs, microsatellites, random sequences, and BAC endsequences are denoted above the long horizontal line. For markers that are present in GDB the same nomenclature has been used.
  • Locus names (D11S####) are listed in parentheses after the primary name if available.
  • STSs derived from BAC endsequences are listed with the BAC name first followed by L or R for the left and right end of the clone, respectively. The two large arrows indicate the genetic markers that define the HBM critical region.
  • Figs. 3A-3F show the genomic structure of Zmax1 with flanking intron sequences. Translation is initiated by the underlined "ATG” in exon 1.
  • the site of the polymorphism in the HBM gene is in exon 3 and is represented by the underlined "G,” whereby this nucleotide is a "T” in the HBM gene.
  • exon 23 (exon 1, SEQ ID NO:40; exon 2, SEQ ID NO:41; exon 3, SEQ ID NO:42; exon 4, SEQ ID NO:43; exon 5, SEQ ID NO:44; exon 6, SEQ ID NO:45; exon 7, SEQ ID NO:46; exon 8, SEQ ID NO:47; exon 9, SEQ ID NO:48; exon 10, SEQ ID NO:49; exon 11, SEQ ID NO:50; exon 12, SEQ ID NO:51; exon 13, SEQ ID NO:52; exon 14, SEQ ID NO:53; exon 15, SEQ ID NO:54; exon 16, SEQ ID NO:55; exon 17, SEQ ID NO:56; exon 18, SEQ ID NO:57; exon 19, SEQ ID NO:58; exon 20, SEQ ID NO:59; exon 21, SEQ ID NO:60; exon 22, SEQ ID NO:61; and exon 23; SEQ ID NO:62).
  • Fig. 4 shows the domain organization of Zmax1, including the YWTD spacers, the extracellular attachment site, the binding site for LDL and calcium, the cysteine-rich growth factor repeats, the transmembrane region, the ideal PEST region with the CK-II phosphorylation site and the internalization domain.
  • Fig. 4 also shows the site of the glycine to valine change that occurs in the HBM protein.
  • the signal peptide is located at amino acids 1-22
  • the extracellular domain is located at amino acids 23-1385
  • the transmembrane segment is located at amino acids 1386-1413
  • the cytoplasmic domain is located at amino acids 1414-1615.
  • Fig. 5 is a schematic illustration of the BAC contigs B527D12 and B200E21 in relation to the HBM gene.
  • Figs. 6A-6E are the nucleotide and amino acid sequences of the wild-type gene, Zmax1.
  • This allelic variant is the HBM gene.
  • the HBM gene encodes for a protein with an amino acid substitution of glycine to valine at position 171.
  • Figs. 7A and 7B are northern blot analyses showing the expression of Zmax1 in various tissues.
  • Fig. 8 is a PCR product analysis.
  • Fig. 9 is allele specific oligonucleotide detection of the Zmax1 exon 3 mutation.
  • Fig.10 is the cellular localization of mouse Zmax1 by in situ hybridization at 100X magnification using sense and antisense probes.
  • Fig. 11 is the cellular localization of mouse Zmax1 by in situ hybridization at 400X magnification using sense and antisense probes.
  • Fig.12 is the cellular localization of mouse Zmax1 by in situ hybridization of osteoblasts in the endosteum at 400X magnification using sense and antisense probes.
  • Fig. 13 shows antisense inhibition of Zmax1 expression in MC-3T3 cells.
  • Fig. 14 shows a Zmax1 Exon3 Allele Specific Oligonucleotide (ASO) assay which illustrates the rarity of the HBM1 allele (right panels; T-specific oligo; 58°C Wash) as compared to the wild-type Zmax1 allele (left panels, G-specific oligo; 55°C Wash). The positive spots appearing in the right panels were positive controls.
  • ASO Allele Specific Oligonucleotide
  • Fig.15 depicts a model representing the potential role of Zmax1 in focal adhesion signaling.
  • Gene refers to a DNA sequence that encodes through its template or messenger RNA a sequence of amino acids characteristic of a specific peptide.
  • the term “gene” includes intervening, non-coding regions, as well as regulatory regions, and can include 5' and 3' ends.
  • Gene sequence refers to a DNA molecule, including both a DNA molecule which contains a non-transcribed or non-translated sequence. The term is also intended to include any combination of gene(s), gene fragment(s), non-transcribed sequence(s) or non-translated sequence(s) which are present on the same DNA molecule.
  • sequences of the present invention may be derived from a variety of sources including DNA, cDNA, synthetic DNA, synthetic RNA or combinations thereof. Such sequences may comprise genomic DNA which may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with promoter regions or poly (A) sequences. The sequences, genomic DNA or cDNA may be obtained in any of several ways. Genomic DNA can be extracted and purified from suitable cells by means well known in the art. Alternatively, mRNA can be isolated from a cell and used to produce cDNA by reverse transcription or other means.
  • cDNA refers to complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase).
  • a "cDNA clone” means a duplex DNA sequence complementary to an RNA molecule of interest, carried in a cloning vector or PCR amplified. This term includes genes from which the intervening sequences have been removed.
  • Recombinant DNA means a molecule that has been recombined by in vitro splicing cDNA or a genomic DNA sequence.
  • Codoning refers to the use of in vitro recombination techniques to insert a particular gene or other DNA sequence into a vector molecule. In order to successfully clone a desired gene, it is necessary to use methods for generating DNA fragments, for joining the fragments to vector molecules, for introducing the composite DNA molecule into a host cell in which it can replicate, and for selecting the clone having the target gene from amongst the recipient host cells.
  • cDNA library refers to a collection of recombinant DNA molecules containing cDNA inserts which together comprise the entire genome of an organism. Such a cDNA library can be prepared by methods known to one skilled in the art and described by, for example, Cowell and Austin, "cDNA Library Protocols," Methods in Molecular Biology (1997). Generally, RNA is first isolated from the cells of an organism from whose genome it is desired to clone a particular gene.
  • Codoning vehicle refers to a plasmid or phage DNA or other DNA sequence which is able to replicate in a host cell.
  • the cloning vehicle is characterized by one or more endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the DNA, which may contain a marker suitable for use in the identification of transformed cells.
  • “Expression control sequence” refers to a sequence of nucleotides that control or regulate expression of structural genes when operably linked to those genes. These include, for example, the lac systems, the trp system, major operator and promoter regions of the phage lambda, the control region of fd coat protein and other sequences known to control the expression of genes in prokaryotic or eukaryotic cells. Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host, and may contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements and/or translational initiation and termination sites.
  • “Expression vehicle” refers to a vehicle or vector similar to a cloning vehicle but which is capable of expressing a gene which has been cloned into it, after transformation into a host.
  • the cloned gene is usually placed under the control of (i.e., operably linked to) an expression control sequence.
  • “Operator” refers to a DNA sequence capable of interacting with the specific repressor, thereby controlling the transcription of adjacent gene(s).
  • Promoter refers to a DNA sequence that can be recognized by an RNA polymerase. The presence of such a sequence permits the RNA polymerase to bind and initiate transcription of operably linked gene sequences.
  • Promoter region is intended to include the promoter as well as other gene sequences which may be necessary for the initiation of transcription. The presence of a promoter region is sufficient to cause the expression of an operably linked gene sequence.
  • “Operably linked” means that the promoter controls the initiation of expression of the gene.
  • a promoter is operably linked to a sequence of proximal DNA if upon introduction into a host cell the promoter determines the transcription of the proximal DNA sequence(s) into one or more species of RNA.
  • a promoter is operably linked to a DNA sequence if the promoter is capable of initiating transcription of that DNA sequence.
  • Prokaryote refers to all organisms without a true nucleus, including bacteria.
  • Eukaryote refers to organisms and cells that have a true nucleus, including mammalian cells.
  • “Host” includes prokaryotes and eukaryotes, such as yeast and filamentous fungi, as well as plant and animal cells.
  • the term includes an organism or cell that is the recipient of a replicable expression vehicle.
  • “Fragment” of a gene refers to any variant of the gene that possesses the biological activity of that gene.
  • Variant refers to a gene that is substantially similar in structure and biological activity or immunological characteristics to either the entire gene or to a fragment of the gene. Provided that the two genes possess a similar activity, they are considered variant as that term is used herein even if the sequence of amino acid residues is not identical.
  • Amplification of nucleic acids refers to methods such as polymerase chain reaction (PCR), ligation amplification (or ligase chain reaction, LCR) and amplification methods based on the use of Q-beta replicase. These methods are well known in the art and described, for example, in U.S. Patent Nos. 4,683,195 and 4,683,202 . Reagents and hardware for conducting PCR are commercially available. Primers useful for amplifying sequences from the HBM region are preferably complementary to, and hybridize specifically to sequences in the HBM region or in regions that flank a target region therein. HBM sequences generated by amplification may be sequenced directly. Alternatively, the amplified sequence(s) may be cloned prior to sequence analysis.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • Antibodies may refer to polyclonal and/or monoclonal antibodies and fragments thereof, and immunologic binding equivalents thereof, that can bind to the HBM proteins and fragments thereof or to nucleic acid sequences from the HBM region, particularly from the HBM locus or a portion thereof.
  • the term antibody is used both to refer to a homogeneous molecular entity, or a mixture such as a serum product made up of a plurality of different molecular entities.
  • Proteins may be prepared synthetically in a protein synthesizer and coupled to a carrier molecule and injected over several months into rabbits. Rabbit sera is tested for immunoreactivity to the HBM protein or fragment.
  • Monoclonal antibodies may be made by injecting mice with the proteins, or fragments thereof Monoclonal antibodies will be screened by ELISA and tested for specific immunoreactivity with HBM protein or fragments thereof. Harlow et al, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988 ). These antibodies will be useful in assays as well as pharmaceuticals.
  • HBM high bone mass
  • HBM protein refers to a protein that is identical to a Zmax1 protein except that it contains an alteration of glycine 171 to valine.
  • An HBM protein is defined for any organism that encodes a Zmax1 true homologue.
  • a mouse HBM protein refers to the mouse Zmax1 protein having the glycine 170 to valine substitution.
  • HBM gene refers to the genomic DNA sequence found in individuals showing the HBM characteristic or phenotype, where the sequence encodes the protein indicated by SEQ ID NO: 4.
  • the HBM gene and the Zmax1 gene are allelic.
  • the protein encoded by the HBM gene has the property of causing elevated bone mass, while the protein encoded by the Zmax1 gene does not.
  • the HBM gene and the Zmax1 gene differ in that the HBM gene has a thymine at position 582, while the Zmax1 gene has a guanine at position 582.
  • the HBM gene comprises the nucleic acid sequence shown as SEQ ID NO: 2.
  • the HBM gene may also be referred to as an "HBM polymorphism.”
  • Normal,” “wild-type,” “unaffected” and “Zmax1” all refer to the genomic DNA sequence that encodes the protein indicated by SEQ ID NO: 3.
  • the Zmax1 gene has a guanine at position 582.
  • the Zmax1 gene comprises the nucleic acid sequence shown as SEQ ID NO: 1.
  • Normal,” “wild-type,” “unaffected” and “Zmax1” also refer to allelic variants of the genomic sequence that encodes proteins that do not contribute to elevated bone mass.
  • the Zmax1 gene is common in the human population, while the HBM gene is rare.
  • SYWT+EGF refers to a repeat unit found in the Zmax1 protein, consisting of five YWT repeats followed by an EGF repeat.
  • Bone development generally refers to any process involved in the change of bone over time, including, for example, normal development, changes that occur during disease states, and changes that occur during aging.
  • Bone development disorder particularly refers to any disorders in bone development including, for example, changes that occur during disease states and changes that occur during aging. Bone development may be progressive or cyclical in nature. Aspects of bone that may change during development include, for example, mineralization, formation of specific anatomical features, and relative or absolute numbers of various cell types.
  • Bone modulation or “modulation of bone formation” refers to the ability to affect any of the physiological processes involved in bone remodeling, as will be appreciated by one skilled in the art, including, for example, bone resorption and appositional bone growth, by, inter alia, osteoclastic and osteoblastic activity, and may comprise some or all of bone formation and development as used herein.
  • Normal bone density refers to a bone density within two standard deviations of a Z score of 0.
  • Zmax1 system refers to a purified protein, cell extract, cell, animal, human or any other composition of matter in which Zmax1 is present in a normal or mutant form.
  • a “surrogate marker” refers to a diagnostic indication, symptom, sign or other feature that can be observed in a cell, tissue, human or animal that is correlated with the HBM gene or elevated bone mass or both, but that is easier to measure than bone density.
  • the general concept of a surrogate marker is well accepted in diagnostic medicine.
  • Zmax1 gene and Zmax1 protein in the forms indicated by SEQ ID NOS: 1 and 3, respectively, and other closely related variants, as well as the adjacent chromosomal regions of Zmax1 necessary for its accurate expression are referred to least 15 contiguous nucleotides of the nucleic acid sequence of SEQ ID NO:1 are referred to in one instance.
  • the present invention also encompasses the HBM gene and HBM protein in the forms indicated by SEQ ID NO: 2 and 4, respectively, and other closely related variants, as well as the adjacent chromosomal regions of the HBM gene necessary for its accurate expression.
  • the present invention is directed to at least 15 contiguous nucleotides of the nucleic acid sequence of SEQ ID NO: 2 wherein said is contiguous nucleotides comprise position 582 of SEQ ID No:2. More preferably in one instance, the present invention is therefore directed to at least 15 contiguous nucleotides of the nucleic acid sequence of SEQ ID NO: 2, wherein one of the 15 contiguous nucleotides is the thymine at nucleotide 582.
  • the invention also relates to the nucleotide sequence of the Zmax1 gene region, as well as the nucleotide sequence of the HBM gene region. More particularly, a preferred embodiment are the BAC clones containing segments of the Zmax1 gene region B200E21-H and B527D12-H. A preferred embodiment is the nucleotide sequence of the BAC clones consisting of SEQ ID NOS: 5-12.
  • the invention also concerns the use of the nucleotide sequence to identify DNA probes for the Zmax1 gene and the HBM gene, PCR primers to amplify the Zmax1 gene and the HBM gene, nucleotide polymorphisms in the Zmax1 gene and the HBM gene, and regulatory elements of the Zmax1 gene and the HBM gene.
  • This invention describes the further localization of the chromosomal location of the Zmax1 gene and HBM gene on chromosome 11a13.3 between genetic markers D11S987 and SNP_CONTIG033-6, as well as the DNA sequences of the Zmax1 gene and the HBM gene.
  • the chromosomal location was refined by the addition of more genetic markers to the mapping panel used to map the gene, and by the extension of the pedigree to include more individuals.
  • the pedigree extension was critical because the new individuals that have been genotyped harbor critical recombination events that narrow the region. To identify genes in the region on 11q13.3, a set of BAC clones containing this chromosomal region was identified.
  • the BAC clones served as a template for genomic DNA sequencing, and also as a reagent for identifying coding sequences by direct cDNA selection. Genomic sequencing and direct cDNA selection were used to characterize more than 1.5 million base pairs of DNA from 11q13.3. The Zmax1 gene was identified within this region and the HBM gene was then discovered after mutational analysis of affected and unaffected individuals.
  • the genes in this region can be characterized at the molecular level by a series of steps that include: cloning of the entire region of DNA in a set of overlapping clones (physical mapping), characterization of genes encoded by these clones by a combination of direct cDNA selection, exon trapping and DNA sequencing (gene identification), and identification of mutations in these genes by comparative DNA sequencing of affected and unaffected members of the HBM kindred (mutation analysis).
  • Physical mapping is accomplished by screening libraries of human DNA cloned in vectors that are propagated in E . coli or S . cereviseae using PCR assays designed to amplify unique molecular landmarks in the chromosomal region of interest.
  • a library of human DNA cloned in Bacterial Artificial Chromosomes (BACs) was screened with a set of Sequence Tagged Site (STS) markers that had been previously mapped to chromosome 11q12-q13 by the efforts of the Human Genome Project.
  • STSs are unique molecular landmarks in the human genome that can be assayed by PCR.
  • the physical map is tied to the genetic map because the markers used for genetic mapping can also be used as STSs for physical mapping.
  • BACs are cloning vectors for large (80 kilobase to 200 kilobase) segments of human or other DNA that are propagated in E . coli.
  • a library of BAC clones is screened so that individual clones harboring the DNA sequence corresponding to a given STS or set of STSs are identified.
  • the STS markers are spaced approximately 20 to 50 kilobases apart, so that an individual BAC clone typically contains at least two STS markers.
  • the BAC libraries that were screened contain enough cloned DNA to cover the human genome six times over. Therefore, an individual STS typically identifies more than one BAC clone.
  • BAC contigs By screening a six-fold coverage BAC library with a series of STS markers spaced approximately 50 kilobases apart, a physical map consisting of a series of overlapping BAC clones, i.e. BAC contigs, can be assembled for any region of the human genome. This map is closely tied to the genetic map because many of the STS markers used to prepare the physical map are also genetic markers.
  • the physical map is first constructed from a set of STSs that have been identified through the publicly available literature and World Wide Web resources.
  • the initial map consists of several separate BAC contigs that are separated by gaps of unknown molecular distance.
  • To identify BAC clones that fill these gaps it is necessary to develop new STS markers from the ends of the clones on either side of the gap. This is clone by sequencing the terminal 200 to 300 base pairs of the BACs flanking the gap, and developing a PCR assay to amplify a sequence of 100 or more base pairs.
  • the new STS can be used to screen the BAC library to identify additional BACs that contain the DNA from the gap in the physical map.
  • this set of overlapping clones serves as a template for identifying the genes encoded in the chromosomal region.
  • Gene identification can be accomplished by many methods. Three methods are commonly used: (1) a set of BACs selected from the BAC contig to represent the entire chromosomal region can be sequenced, and computational methods can be used to identify all of the genes, (2) the BACs from the BAC contig can be used as a reagent to clone cDNAs corresponding to the genes encoded in the region by a method termed direct cDNA selection, or (3) the BACs from the BAC contig can be used to identify coding sequences by selecting for specific DNA sequence motifs in a procedure called exon trapping.
  • the present invention includes genes identified by the first two methods.
  • BACs To sequence the entire BAC contig representing the HBM candidate region, a set of BACs was chosen for subcloning into plasmid vectors and subsequent DNA sequencing of these subclones. Since the DNA cloned in the BACs represents genomic DNA, this sequencing is referred to as genomic sequencing to distinguish it from cDNA sequencing.
  • genomic sequencing To initiate the genomic sequencing for a chromosomal region of interest, several non-overlapping BAC clones are chosen. DNA for each BAC clone is prepared, and the clones are sheared into random small fragments which are subsequently cloned into standard plasmid vectors such as pUC18. The plasmid clones are then grown to propagate the smaller fragments, and these are the templates for sequencing.
  • BAC DNA sequence sufficient plasmid clones are sequenced to yield six-fold coverage of the BAC clone. For example, if the BAC is 100 kilobases long, then phagemids are sequenced to yield 600 kilobases of sequence. Since the BAC DNA was randomly sheared prior to cloning in the phagemid vector, the 600 kilobases of raw DNA sequence can be assembled by computational methods into overlapping DNA sequences termed sequence contigs. For the purposes of initial gene identification by computational methods, six-fold coverage of each BAC is sufficient to yield ten to twenty sequence contigs of 1000 base pairs to 20,000 base pairs.
  • the sequencing strategy employed in this invention was to initially sequence "seed" BACs from the BAC contig in the HBM candidate region. The sequence of the "seed” BACs was then used to identify minimally overlapping BACs from the contig, and these were subsequently sequenced. In this manner, the entire candidate region was sequenced, with several small sequence gaps left in each BAC. This sequence served as the template for computational gene identification.
  • One method for computational gene identification is to compare the sequence of BAC contig to publicly available databases of cDNA and genomic sequences, e.g. unigene, dbEST, genbank. These comparisons are typically done using the BLAST family of computer algorithms and programs ( Altschul et al, J. Mol.
  • the BAC sequence can also be translated into protein sequence, and the protein sequence can be used to search publicly available protein databases, using a version of BLAST designed to analyze protein sequences ( Altschul et al, Nucl. Acids Res., 25:3389-3402 (1997 )). Another method is to use computer algorithms such as MZEF ( Zhang, Proc. Natl. Acad.
  • genes were also identified by direct cDNA selection ( Del Mastro et al, Genome Res. 5(2):185-194 (1995 )).
  • direct cDNA selection cDNA pools from tissues of interest are prepared, and the BACs from the candidate region are used in a liquid hybridization assay to capture the cDNAs which base pair to coding regions in the BAC.
  • the cDNA pools were created from several different tissues by random priming the first strand cDNA from polyA RNA, synthesizing the second strand cDNA by standard methods, and adding linkers to the ends of the cDNA fragments. The linkers are used to amplify the cDNA pools.
  • the BAC clones are used as a template for in vitro DNA synthesis to create a biotin labelled copy of the BAC DNA.
  • the biotin labelled copy of the BAC DNA is then denatured and incubated with an excess of the PCR amplified, linkered cDNA pools which have also been denatured.
  • the BAC DNA and cDNA are allowed to anneal in solution, and heteroduplexes between the BAC and the cDNA are isolated using streptavidin coated magnetic beads.
  • the cDNAs that are captured by the BAC are then amplified using primers complimentary to the linker sequences, and the hybridization/selection process is repeated for a second round. After two rounds of direct cDNA selection, the cDNA fragments are cloned, and a library of these direct selected fragments is created.
  • the cDNA clones isolated by direct selection are analyzed by two methods. Since a pool of BACs from the HBM candidate region is used to provide the genomic DNA sequence, the cDNAs must be mapped to individual BACs. This is accomplished by arraying the BACs in microtiter dishes, and replicating their DNA in high density grids. Individual cDNA clones are then hybridized to the grid to confirm that they have sequence identity to an individual BAC from the set used for direct selection, and to determine the specific identity of that BAC. cDNA clones that are confirmed to correspond to individual BACs are sequenced. To determine whether the cDNA clones isolated by direct selection share sequence identity or similarity to previously identified genes, the DNA and protein coding sequences are compared to publicly available databases using the BLAST family of programs.
  • genomic DNA sequence and cDNA sequence provided by BAC sequencing and by direct cDNA selection yields an initial list of putative genes in the region.
  • the genes in the region were all candidates for the HBM locus.
  • Northern blots were performed to determine the size of the transcript corresponding to each gene, and to determine which putative exons were transcribed together to make an individual gene.
  • probes were prepared from direct selected cDNA clones or by PCR amplifying specific fragments from genomic DNA or from the BAC encoding the putative gene of interest. The Northern blots gave information on the size of the transcript and the tissues in which it was expressed. For transcripts which were not highly expressed, it was sometimes necessary to perform a reverse transcription PCR assay using RNA from the tissues of interest as a template for the reaction.
  • Gene identification by computational methods and by direct cDNA selection provides unique information about the genes in a region of a chromosome. When genes are identified, then it is possible to examine different individuals for mutations in each gene.
  • BMC bone mineral content
  • BMD bone mineral density
  • the HBM phenotype is defined by the following criteria: very high spinal BMD; a clinical history devoid of any known high bone mass syndrome; and skeletal radiographs showing a normal shape of the appendicular skeleton.
  • GTC_HBM_Marker_1, GTC_HBM_Marker_2, GTC_HBM_Marker_3, GTC_HBM_Marker_4, GTC_HBM_Marker_5, GTC_HBM_Marker_6, and GTC_HBM_Marker_7 See Fig. 2 ).
  • the DNA extraction procedure used a kit purchased from Gentra Systems, Inc. (Minneapolis, Minnesota). Briefly, the procedure involved adding 3 volumes of a red blood cell lysis buffer to the whole blood. After incubations for 10 minutes at room temperature, the solution was centrifuged in a Beckman tabletop centrifuge at 2,000 X g for 10 minutes. The white blood cell pellet was resuspended in Cell Lysis Buffer. Once the pellet was completely resuspended and free of cell clumps, the solution was digested with RNase A for 15 minutes at 37°C. Proteins were precipitated by addition of the provided Protein Precipitation Solution and removed by centrifugation. The DNA was precipitated out of the supernatant by addition of isopropanol.
  • DNA was genotyped using one fluorescently labeled oligonucleotide primer and one unlabeled oligonucleotide primer.
  • Labeled and unlabeled oligonucleotides were obtained from Integrated DNA Technologies, Inc. (Coralville, Iowa). All other reagents for microsatellite genotyping were purchased from Perkin Elmer-Applied Biosystems, Inc. ("PE-ABI") (Norwalk, Connecticut). Individual PCR reactions were performed for each marker, as described by PE-ABI using AmpliTag DNA Polymerase. The reactions were added to 3.5 ⁇ l of loading buffer containing deionized formamide, blue dextran and TAMRA 350 size standards (PE-ABI).
  • Fig. 1 demonstrates the pedigree of the individuals used in the genetic linkage studies for this invention. Specifically, two-point linkage analysis was performed using the MLINK and LINKMAP components of the program LINKAGE ( Lathrop et al, Am. J. Hum. Genet., 37:482-498 (1985 )). Pedigree/marker data was exported from Cyrillic as a pre-file into the Makeped program and converted into a suitable ped-file for linkage analysis.
  • the original linkage analysis was performed using three models: (i) an autosomal dominant, fully penetrant model, (ii) an autosomal dominant model with reduced penetrance, and (iii) a quantitative trait model.
  • the HBM locus was mapped to chromosome 11q12-13 by analyzing DNA for linked markers from 22 members of a large, extended kindred. A highly automated technology was used with a panel of 345 fluorescent markers which spanned the 22 autosomes at a spacing interval ranging from 6-22 cM. Only markers from this region of chromosome 11 showed evidence of linkage (LOD score ⁇ 3.0). The highest LOD score (5.74) obtained by two-point and multipoint analysis was D11S987 (map position 55 in Fig. 2 ).
  • the 95% confidence interval placed the HBM locus between markers D11S905 and D11S937 (map position 41-71 in Fig. 2 ). Haplotype analysis also places the Zmax1 gene in this same region. Further descriptions of the markers D11S987, D11S905, and D11S937 can be found in Gyapay et al, Nature Genetics, Vol. 7, (1994 ).
  • the inventors report the narrowing of the HBM interval to the region between markers D11S987 and GTC_HBM_Marker_5. These two markers lie between the delimiting markers from the original analysis (D11S11S905 and D11S937) and are approximately 3 cM from one another.
  • the narrowing of the interval was accomplished using genotypic data from the markers D11S4191, D11S1883, D11S1785, D11S4113, D11S4136, D11S4139, ( Dib et al, Nature, 380:152-154 (1996 )), FGF3 ( Polymeropolous et al, Nucl.
  • haplotype analysis with the above genetic markers identifies recombination events (crossovers) in individuals 9019 and 9020 that significantly refine the interval of chromosome 11 to which the Zmax1 gene is localized.
  • Individual 9019 is an HBM-affected individual that inherits a portion of chromosome 11 from the maternal chromosome with the HBM gene, and a portion from the chromosome 11 homologue.
  • the portion inherited from the HBM gene-carrying chromosome includes markers D11S935, D11S1313, GTC_HBM_Marker_4, D11S987, D11S1296, GTC_HBM_Marker_6, GTC_HBM_Marker_2, D11S970, GTC_HBM_Marker_3, D11S4113, GTC_HBM__Marker_1, GTC_HBM_Marker_7 and GTC_HBM_Marker_5.
  • the portion from D11S4136 and continuing in the telomeric direction is derived from the non-HBM chromosome. This data places the Zmax1 gene in a location centromeric to the marker GTC_HBM_Marker_5.
  • Individual 9020 is an unaffected individual who also exhibits a critical recombination event.
  • This individual inherits a recombinant paternal chromosome 11 that includes markers D11S935, D11S1313, GTC_HBM_Marker_4, D11S987, D11S1296 and GTC_HBM_Marker_6 from her father's (individual 0115) chromosome 11 homologue that carries the HBM gene, and markers GTC_HBM_Marker_2, D11S970, GTC_HBM_Marker_3, GTC_HBM_Marker_1, GTC_HBM_Marker_7, GTC_HBM_Marker_5, D11S4136, D11S4139, D11S1314, and D11S937 from her father's chromosome 11 that does not carry the HBM gene.
  • Marker D11S4113 is uninformative due to its homozygous nature in individual 0115. This recombination event places the centro
  • Two-point linkage analysis was also used to confirm the location of the Zmax1 gene on chromosome 11.
  • the linkage results for two point linkage analysis under a model of full penetrance are presented in Table 1 below.
  • This table lists the genetic markers in the first column and the recombination fractions across the top of the table. Each cell of the column shows the LOD score for an individual marker tested for linkage to the Zmax1 gene at the recombination fraction shown in the first row. For example, the peak LOD score of 7.66 occurs at marker D11S970, which is within the interval defined by haplotype analysis.
  • a single nucleotide polymorphism further defines the HBM region.
  • This SNP is termed SNP_Contig033-6 and is located 25 kb centromeric to the genetic marker GTC_HBM_Marker_5.
  • This SNP is telomeric to the genetic marker GTC_HBM_Marker_7.
  • SNP_Contig033-6 is present in HBM-affected individual 0113. However, the HBM-affected individual 9019, who is the son of 0113, does not carry this SNP. Therefore, this indicates that the crossover is centromeric to this SNP.
  • the primer sequence for the genetic markers GTC_HBM_Marker_5 and GTC_HBM_Marker_7 is shown in Table 2 below.
  • the kindred described have several features of great interest, the most important being that their bones, while very dense, have an absolutely normal shape.
  • the outer dimensions of the skeletons of the HBM-affected individuals are normal, and, while medullary cavities are present, there is no interference with hematopoiesis.
  • the HBM-affected members seem to be resistant to fracture, and there are no neurologic symptoms, and no symptoms of impairment of any organ or system function in the members examined. HBM-affected members of the kindred live to advanced age without undue illness or disability.
  • the HBM phenotype matches no other bone disorders such as osteoporosis, osteoporosis pseudoglioma, Engelmann's disease, Ribbing's disease, hyperphosphatasemia, Van Buchem's disease, melorheostosis, osteopetrosis, pycnodysostosis, sclerostenosis, osteopoikilosis, acromegaly, Paget's disease, fibrous dysplasia, tubular stenosis, osteogenesis imperfecta, hypoparathyroidism, pseudohypoparathyroidism, pseudopseudohypoparathyroidism, primary and secondary hyperparathyroidism and associated syndromes, hypercalciuria, medullary carcinoma of the thyroid gland, osteomalacia and other diseases.
  • the HBM locus in this family has a very powerful and substantial role in regulating bone density, and its identification is an important step in understanding the pathway(s) that regulate bone density and the pathogenesis of diseases such as osteo
  • HBM gene is a suppressor of osteoporosis.
  • individuals carrying the HBM gene are dosed with the HBM protein, and, as a result, do not develop osteoporosis. This in vivo observation is strong evidence that treatment of normal individuals with the HBM gene or protein, or a fragment thereof, will ameliorate osteoporosis.
  • the genetic mapping data described above were used to construct a physical map of the region containing Zmax1 on chromosome 11q13.3.
  • the physical map consists of an ordered set of molecular landmarks, and a set of BAC clones that contain the Zmax1 gene region from chromosome 11q13.3.
  • Maps were integrated manually to identify markers mapping to the region containing Zmax1.
  • Table 3 shows the STS markers used to prepare the physical map of the Zmax1 gene region.
  • Novel STSs were developed either from publicly available genomic sequence or from sequence-derived BAC insert ends. Primers were chosen using a script which automatically performs vector and repetitive sequence masking using Cross_match (P. Green, U. of Washington) and subsequent primer picking using Primer3 (Rozen, Skaletsky (1996, 1997). Primer3 is available at www.genome.wi.mit. edu/genome_software/other/primer3.html.
  • PCR Polymerase chain reaction
  • Cycling conditions included an initial denaturation at 94°C for 2 minutes followed by 40 cycles at 94°C for 15 seconds, 55 °C for 25 seconds, and 72°C for 25 seconds followed by a final extension at 72°C for 3 minutes. Depending on the results from the initial round of optimization the conditions were further optimized if necessary. Variables included increasing the annealing temperature to 58°C or 60°C, increasing the cycle number to 42 and the annealing and extension times to 30 seconds, and using AmpliTaqGold (Perkin Elmer).
  • BAC clones ( Kim et al, Genomics, 32:213-218 (1996 ), Shizuya et al, Proc. Natl. Acad. Sci. USA, 89:8794-8797 (1992 )) containing STS markers of interest were obtained by PCR-based screening of DNA pools from a total human BAC library purchased from Research Genetics. DNA pools derived from library plates 1-596 were used corresponding to nine genomic equivalents of human DNA. The initial screening process involved PCR reactions of individual markers against superpools, i.e., a mixture of DNA derived from all BAC clones from eight 384-well library plates. For each positive superpool, plate (8), row (16) and column (24) pools were screened to identify a unique library address.
  • PCR products were electrophoresed in 2% agarose gels (Sigma) containing 0.5 ⁇ g/ml ethidium bromide in 1X TBE at 150 volts for 45 min.
  • the electrophoresis units used were the Model A3-1 systems from Owl Scientific Products.
  • gels contained 10 tiers of lanes with 50 wells/tier.
  • Molecular weight markers 100 bp ladder, Life Technologies, Bethesda, MD) were loaded at both ends of the gel. Images of the gels were captured with a Kodak DC40 CCD camera and processed with Kodak 1D software.
  • the gel data were exported as tab delimited text files; names of the files included information about the library screened, the gel image files and the marker screened. These data were automatically imported using a customized Perl script into FilemakerTM PRO (Claris Corp.) databases for data storage and analysis. In cases where incomplete or ambiguous clone address information was obtained, additional experiments were performed to recover a unique, complete library address.
  • Bacteria were grown in 15 ml Terrific Broth containing 12.5 ⁇ g/ml chloramphenicol in a 50 ml conical tube at 37°C for 20 hrs with shaking at 300 rpm. The cultures were centrifuged in a Sorvall RT 6000 D at 3000 rpm ( ⁇ 1800 g) at 4°C for 15 min. The supernatant was then aspirated as completely as possible. In some cases cell pellets were frozen at -20°C at this step for up to 2 weeks. The pellet was then vortexed to homogenize the cells and minimize clumping.
  • P1 solution 50 mM glucose, 15 mM Tris-HCl, pH 8, 10 mM EDTA, and 100 ⁇ g/ml RNase A
  • P2 solution 50 mM glucose, 15 mM Tris-HCl, pH 8, 10 mM EDTA, and 100 ⁇ g/ml RNase A
  • P2 solution 0.2 N NaOH, 1% SDS
  • P3 solution 3 M KOAc, pH 5.5
  • the solution was incubated on ice for 5 min. and then centrifuged at 4°C in a microfuge for 10 min.
  • BACs were inoculated into 15 ml of 2X LB Broth containing 12.5 ⁇ g/ml chloramphenicol in a 50 ml conical tube. 4 tubes were inoculated for each clone. Cultures were grown overnight ( ⁇ 16 hr) at 37°C with vigorous shaking (>300 rpm). Standard conditions for BAC DNA isolation were followed as recommended by the Autogen 740 manufacturer. 3 ml samples of culture were placed into Autogen tubes for a total of 60 ml or 20 tubes per clone. Samples were dissolved finally in 100 ⁇ l TE8 with 15 seconds of shaking as part of the Autogen protocol.
  • DNA solutions were transferred from each individual tube and pooled into a 2 ml Eppendorf tube. Tubes with large amounts of debris (carry over from the pelleting debris step) were avoided. The tubes were then rinsed with 0.5 ml of TE8 successively and this solution added to the pooled material. DNA solutions were stored at 4°C; clumping tended to occur upon freezing at -20°C. This DNA was either used directly for restriction mapping, CHEF gel analysis or FISH mapping or was further purified as described below for use in endsequencing reactions.
  • the volume of DNA solutions was adjusted to 2 ml with TE8, samples were then mixed gently and heated at 65 °C for 10 min. The DNA solutions were then centrifuged at 4°C for 5 min. and the supernatants transferred to a 15 ml conical tube. The NaCl concentration was then adjusted to 0.75 M ( ⁇ 0.3 ml of 5 M NaCl to the 2 ml sample). The total volume was then adjusted to 6 ml with Qiagen column equilibration buffer (Buffer QBT). The supernatant containing the DNA was then applied to the column and allowed to enter by gravity flow. Columns were washed twice with 10 ml of Qiagen Buffer QC.
  • Buffer QBT Qiagen column equilibration buffer
  • Bound DNA was then eluted with four separate 1 ml aliquots of Buffer QF kept at 65°C. DNA was precipitated with 0.7 volumes of isopropanol ( ⁇ 2.8 ml). Each sample was then transferred to 4 individual 2.2 ml Eppendorf tubes and incubated at room temperature for 2 hr or overnight. Samples were centrifuged in a microfuge for 10 min. at 4°C. The supernatant was removed carefully and 1 ml of 70% ethanol was added. Samples were centrifuged again and because the DNA pellets were often loose at this stage, the supernatant removed carefully. Samples were centrifuged again to concentrate remaining liquid which was removed with a micropipet tip.
  • DNA pellets were then dried in a desiccator for 10 min. 20 ⁇ l of sterile distilled and deionized H 2 O was added to each tube which was then placed at 4°C overnight. The four 20 ⁇ l samples for each clone were pooled and the tubes rinsed with another 20 ⁇ l of sterile distilled and deionized H 2 O for a final volume of 100 ⁇ l. Samples were then heated at 65°C for 5 min. and then mixed gently. Typical yields were 2-5 ⁇ g/60 ml culture as assessed by NotI digestion and comparison with uncut lambda DNA.
  • the tube units were transferred into an Autogen rack holder and placed into a rotary shaker at 37°C for 16-17 hours at 250 rpm. Following growth, standard conditions for BAC DNA preparation, as defined by the manufacturer, were used to program the Autogen. Samples were not dissolved in TE8 as part of the program and DNA pellets were left dry. When the program was complete, the tubes were removed from the output tray and 30 ⁇ l of sterile distilled and deionized H 2 O was added directly to the bottom of the tube. The tubes were then gently shaken for 2-5 seconds and then covered with parafilm and incubated at room temperature for 1-3 hours. DNA samples were then transferred to an Eppendorf tube and used either directly for sequencing or stored at 4°C for later use.
  • DNA samples prepared either by manual alkaline lysis or the Autogen protocol were digested with HindIII for analysis of restriction fragment sizes. This data were used to compare the extent of overlap among clones. Typically 1-2 ⁇ g were used for each reaction. Reaction mixtures included: 1X Buffer 2 (New England Biolabs), 0.1 mg/ml bovine serum albumin (New England Biolabs), 50 ⁇ g/ml RNase A (Boehringer Mannheim), and 20 units of HindIII (New England Biolabs) in a final volume of 25 ⁇ l. Digestions were incubated at 37°C for 4-6 hours. BAC DNA was also digested with NotI for estimation of insert size by CHEF gel analysis (see below). Reaction conditions were identical to those for HindIII except that 20 units of NotI were used. Six ⁇ l of 6X Ficoll loading buffer containing bromphenol blue and xylene cyanol was added prior to electrophoresis.
  • HindIII digests were analyzed on 0.6% agarose (Seakem, FMC Bioproducts) in 1X TBE containing 0.5 ⁇ g/ml ethidium bromide. Gels (20 cm X 25 cm) were electrophoresed in a Model A4 electrophoresis unit (Owl Scientific) at 50 volts for 20-24 hrs. Molecular weight size markers included undigested lambda DNA, HindIII digested lambda DNA, and HaeIII digested _X174 DNA. Molecular weight markers were heated at 65 °C for 2 min. prior to loading the gel. Images were captured with a Kodak DC40 CCD camera and analyzed with Kodak 1D software.
  • NotI digests were analyzed on a CHEF DRII (BioRad) electrophoresis unit according to the manufacturer's recommendations. Briefly, 1% agarose gels (BioRad pulsed field grade) were prepared in 0.5X TBE, equilibrated for 30 minutes in the electrophoresis unit at 14°C, and electrophoresed at 6 volts/cm for 14 hrs with circulation. Switching times were ramped from 10 sec to 20 sec. Gels were stained after electrophoresis in 0.5 ⁇ g/ml ethidium bromide. Molecular weight markers included undigested lambda DNA, HindIII digested lambda DNA, lambda ladder PFG ladder, and low range PFG marker (all from New England Biolabs).
  • BAC DNA prepared either by the manual alkaline lysis or Autogen protocols were labeled for FISH analysis using a Bioprime labeling kit (BioRad) according to the manufacturer's recommendation with minor modifications. Approximately 200 ng of DNA was used for each 50 ⁇ l reaction. 3 ⁇ l were analyzed on a 2% agarose gel to determine the extent of labeling. Reactions were purified using a Sephadex G50 spin column prior to in situ hybridization. Metaphase FISH was performed as described ( Ma et al, Cytogenet. Cell Genet., 74:266-271 (1996 )).
  • the sequencing of BAC insert ends utilized DNA prepared by either of the two methods described above.
  • the DYEnamic energy transfer primers and Dynamic Direct cycle sequencing kits from Amersham were used for sequencing reactions.
  • Ready made sequencing mix including the M13 -40 forward sequencing primer was used (Catalog # US79730 ) for the T7 BAC vector terminus; ready made sequencing mix (Catalog # US79530 ) was mixed with the M13 -28 reverse sequencing primer (Catalog # US79339 ) for the SP6 BAC vector terminus.
  • the sequencing reaction mixes included one of the four fluorescently labeled dye-primers, one of the four dideoxy termination mixes, dNTPs, reaction buffer, and Thermosequenase.
  • BAC DNA sample 3 ⁇ l of the BAC DNA sample was aliquoted to 4 PCR strip tubes. 2 ⁇ l of one of the four dye primer/termination mix combinations was then added to each of the four tubes. The tubes were then sealed and centrifuged briefly prior to PCR. Thermocycling conditions involved a 1 minute denaturation at 95 °C, 15 second annealing at 45°C, and extension for 1 minute at 70°C for 35 total cycles. After cycling the plates were centrifuged briefly to collect all the liquid to the bottom of the tubes. 5 ⁇ l of sterile distilled and deionized H 2 O was then added into each tube, the plates sealed and centrifuged briefly again. The four samples for each BAC were then pooled together.
  • DNA was then precipitated by adding 1.5 ⁇ l of 7.5 M NH 4 OAc and 100 ⁇ l of -20°C 100% ethanol to each tube. Samples were mixed by pipetting up and down once. The plates were then sealed and incubated on ice for 10 minutes. Plates were centrifuged in a table top Haraeus centrifuge at 4000 rpm (3,290 g) for 30 minutes at 4°C to recover the DNA. The supernatant was removed and excess liquid blotted onto paper towels. Pellets were washed by adding 100 ⁇ l of -20°C 70% ethanol into each tube and recentrifuging at 4000 rpm (3,290 g) for 10 minutes at 4°C.
  • the physical map of the Zmax1 gene region provides a set of BAC clones that contain within them the Zmax1 gene and the HBM gene. DNA sequencing of several of the BACs from the region has been completed.
  • the DNA sequence data is a unique reagent that includes data that one skilled in the art can use to identify the Zmax1 gene and the HBM gene, or to prepare probes to identify the gene(s), or to identify DNA sequence polymorphisms that identify the gene(s).
  • BAC DNA was isolated according to one of two protocols, either a Qiagen purification of BAC DNA (Qiagen, Inc. as described in the product literature) or a manual purification which is a modification of the standard alkaline lysis/Cesium Chloride preparation of plasmid DNA (see e.g., Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons (1997 )).
  • BAC DNA was sheared hydrodynamically using an HPLC ( Hengen, Trends in Biochem. Sci., 22:273-274 (1997 )) to an insert size of 2000-3000 bp. After shearing, the DNA was concentrated and separated on a standard 1% agarose gel. A single fraction, corresponding to the approximate size, was excised from the gel and purified by electroelution ( Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring, NY (1989 )).
  • the purified DNA fragments were then blunt-ended using T4 DNA polymerase.
  • the blunt-ended DNA was then ligated to unique BstXI-linker adapters (5' GTCTTCACCACGGGG and 5' GTGGTGAAGAC in 100-1000 fold molar excess).
  • These linkers were complimentary to the BstXI-cut pMPX vectors (constructed by the inventors), while the overhang was not self-complimentary. Therefore, the linkers would not concatemerize nor would the cut-vector religate itself easily.
  • the linker-adapted inserts were separated from the unincorporated linkers on a 1% agarose gel and purified using GeneClean (BIO 101, Inc.).
  • the linker-adapted insert was then ligated to a modified pBlueScript vector to construct a "shotgun" subclone library.
  • the vector contained an out-of-frame lacZ gene at the cloning site which became in-frame in the event that an adapter-dimer is cloned, allowing these to be avoided by their blue-color.
  • oligo(dT) and random primed cDNA pools from the same tissue, 2.5 ⁇ g mRNA was mixed with oligo(dT) primer in one reaction and 2.5 ⁇ g mRNA was mixed with random hexamers in another reaction, and both were converted to first and second strand cDNA according to manufacturers recommendations (Life Technologies, Bethesda, MD). Paired phosphorylated cDNA linkers (see sequence below) were annealed together by mixing in a 1:1 ratio (10 ⁇ g each) incubated at 65°C for five minutes and allowed to cool to room temperature.
  • Oligo 1/2 was ligated to oligo(dT) and random primed cDNA pools prepared from bone marrow.
  • Oligo 3/4 was ligated to oligo(dT) and random primed cDNA pools prepared from calvarial bone.
  • Oligo 5/6 was ligated to oligo(dT) and random primed cDNA pools prepared from brain and skeletal muscle.
  • Oligo 7/8 was ligated to oligo(dT) and random primed cDNA pools prepared from kidney.
  • Oligo 11/12 was ligated to oligo(dT) and random primed cDNA pools prepared from femoral bone.
  • the cDNA pools were evaluated for length distribution by PCR amplification using 1 ⁇ l of a 1:1, 1:10, and 1:100 dilution of the ligation reaction, respectively.
  • PCR reactions were performed in a Perkin Elmer 9600, each 25 ⁇ l volume reaction contained 1 ⁇ l of DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.001 % gelatin, 200 mM each dNTPs, 10 ⁇ M primer and 1 unit Taq DNA polymerase (Perkin Elmer) and was amplified under the following conditions: 30 seconds at 94°C, 30 seconds at 60°C and 2 minutes at 72°C for 30 cycles.
  • the length distribution of the amplified cDNA pools were evaluated by electrophoresis on a 1% agarose gel.
  • the PCR reaction that gave the best representation of the random primed and oligo(dT) primed cDNA pools was scaled up so that ⁇ 2-3 ⁇ g of each cDNA pool was produced.
  • the starting cDNA for the direct selection reaction comprised of 0.5 ⁇ g of random primed cDNAs mixed with 0.5 ⁇ g of oligo(dT) primed cDNAs.
  • the DNA from the 54 BACs that were used in the direct cDNA selection procedure was isolated using Nucleobond AX columns as described by the manufacturer (The Nest Group, Inc.).
  • the BACs were pooled in equimolar amounts and 1 ⁇ g of the isolated genomic DNA was labeled with biotin 16-UTP by nick translation in accordance with the manufacturers instructions (Boehringer Mannheim). The incorporation of the biotin was monitored by methods that could be practiced by one skilled in the art ( Del Mastro and Lovett, Methods in Molecular Biology, Humana Press Inc., NJ (1996 )).
  • Direct cDNA selection was performed using methods that could be practiced by one skilled in the art ( Del Mastro and Lovett, Methods in Molecular Biology, Humana Press Inc., NJ (1996 )). Briefly, the cDNA pools were multiplexed in two separate reactions: In one reaction cDNA pools from bone marrow, calvarial bone, brain and testis were mixed, and in the other cDNA pools from skeletal muscle, kidney and femoral bone were mixed. Suppression of the repeats, yeast sequences and plasmid in the cDNA pools was performed to a Cot of 20. 100 ng of biotinylated BAC DNA was mixed with the suppressed cDNAs and hybridized in solution to a Cot of 200.
  • the biotinylated DNA and the cognate cDNAs was captured on streptavidin-coated paramagnetic beads. The beads were washed and the primary selected cDNAs were eluted. These cDNAs were PCR amplified and a second round of direct selection was performed. The product of the second round of direct selection is referred to as the secondary selected material.
  • a Galanin cDNA clone previously shown to map to 11q12-13 ( Evans, Genomics, 18:473-477 (1993 )), was used to monitor enrichment during the two rounds of selection.
  • the secondary selected material from bone marrow, calvarial bone, femoral bone, kidney, skeletal muscle, testis and total brain was PCR amplified using modified primers of oligos 1, 3, 5, 7 and 11, shown below, and cloned into the UDG vector pAMP10 (Life Technologies, Bethesda, MD), in accordance with the manufacturer's recommendations.
  • the cDNA sequences were compared to a database containing sequences derived from human repeats, mitochondrial DNA, ribosomal RNA, E. coli DNA to remove background clones from the dataset using the program cross_match. A further round of comparison was also performed using the program BLASTN2 against known genes (Genbank) and the BAC sequences from the HBM region. Those cDNAs that were >90% homologous to these sequences were filed according to the result and the data stored in a database for further analysis. cDNA sequences that were identified but did not have significant similarity to the BAC sequences from the HBM region or were eliminated by cross_match were hybridized to nylon membranes which contained the BACs from the HBM region, to ascertain whether they hybridized to the target.
  • Hybridization analysis was used to map the cDNA clones to the BAC target that selected them.
  • the BACs that were identified from the HBM region were arrayed and grown into a 96 well microtiter plate.
  • LB agar containing 25 ⁇ g/ml kanamycin was poured into 96 well microtiter plate lids. Once the agar had solidified, pre-cut Hybond N+ nylon membranes (Amersham) were laid on top of the agar and the BACs were stamped onto the membranes in duplicate using a hand held 96 well replica plater (V&P Scientific, Inc.). The plates were incubated overnight at 37°C. The membranes were processed according to the manufacturers recommendations.
  • the cDNAs that needed to be mapped by hybridization were PCR amplified using the relevant primer (oligos 1, 3, 5, 7 and 11) that would amplify that clone.
  • the primers were modified to contain a linkered digoxigenin molecule at the 5' of the oligonucleotide.
  • the PCR amplification was performed under the same conditions as described in Preparation of cDNA Pools (above).
  • the PCR products were evaluated for quality and quantity by electrophoresis on a 1% agarose gel by loading 5 ⁇ l of the PCR reaction.
  • the nylon membranes containing the stamped BACs were individually pre-hybridized in 50 ml conical tubes containing 10 ml of hybridization solution (5x SSPE, 0.5x Blotto, 2.5% SDS and 1 mM EDTA (pH 8.0)).
  • the 50 ml conical tubes were placed in a rotisserie oven (Robbins Scientific) for 2 hours at 65°C. Twenty-five ng of each cDNA probe was denatured and added into individual 50 ml conical tubes containing the nylon membrane and hybridization solution. The hybridization was performed overnight at 65°C.
  • the filters were washed for 20 minutes at 65°C in each of the following solutions: 3x SSPE, 0.1% SDS; 1x SSPE, 0.1% SDS and 0.1x SSPE, 0.1% SDS.
  • the membranes were removed from the 50 ml conical tubes and placed in a dish. Acetate sheets were placed between each membrane to prevent them from sticking to each other. The incubation of the membranes with the Anti-DIG-AP and CDP-Star was performed according to manufacturers recommendations (Boehringer Mannheim). The membranes were wrapped in Saran wrap and exposed to Kodak Bio-Max X-ray film for 1 hour.
  • oligonucleotide primers were designed for use in the polymerase chain reaction (PCR) so that portions of a cDNA, EST, or genomic DNA could be amplified from a pool of DNA molecules (a cDNA library) or RNA population (RT-PCR and RACE).
  • the PCR primers were used in a reaction containing genomic DNA to verify that they generated a product of the size predicted based on the genomic (BAC) sequence.
  • BAC genomic sequence.
  • a number of cDNA libraries were then examined for the presence of the specific cDNA or EST. The presence of a fragment of a transcription unit in a particular cDNA library indicates a high probability that additional portions of the same transcription unit will be present as well.
  • a critical piece of data that is required when characterizing novel genes is the length, in nucleotides, of the processed transcript or messenger RNA (mRNA).
  • mRNA messenger RNA
  • One skilled in the art primarily determines the length of an mRNA by Northern blot hybridization ( Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY (1989 )).
  • Groups of ESTs and direct-selected cDNA clones that displayed significant sequence similarity to sequenced BACs in the critical region were grouped for convenience into approximately 30 kilobase units. Within each 30 kilobase unit there were from one up to fifty ESTs and direct-selected cDNA clones which comprised one or more independent transcription units.
  • One or more ESTs or direct-selected cDNAs were used as hybridization probes to determine the length of the mRNA in a variety of tissues, using commercially available reagents (Multiple Tissue Northern blot; Clontech, Palo Alto, California) under conditions recommended by the manufacturer.
  • First strand cDNA synthesis was initiated using an oligonucleotide primer with the sequence: 5'-AACTGGAAGAATTC GCGGCCGC AGGAATTTTTTTTT TTTTTTT-3' (SEQ ID NO:27). This primer introduces a NotI restriction site (underlined) at the 3' end of the cDNA. First and second strand synthesis were performed using the "one-tube" cDNA synthesis kit as described by the anufacturer (Life Technologies, Bethesda, MD).
  • Double stranded cDNAs were treated with T4 polynucleotide kinase to ensure that the ends of the molecules were blunt ( Soares in Automated DNA Sequencing and Analysis, Adams, Fields and Venter, Eds., Academic Press, NY, pages 110-114 (1994 )), and the blunt ended cDNAs were then size selected by a Biogel column ( Huynh et al in DNA Cloning, Vol. 1, Glover, Ed., IRL Press, Oxford, pages 49-78 (1985 )) or with a size-sep 400 sepharose column (Pharmacia, catalog # 27-5105-01). Only cDNAs of 400 base pairs or longer were used in subsequent steps.
  • EcoRI adapters (sequence: 5' OH-AATTCGGCACGAG-OH 3' (SEQ ID NO:28), and 5' p-CTCGTGCCG-OH 3' (SEQ ID NO:29)) were then ligated to the double stranded cDNAs by methods familiar to one skilled in the art (Soares, 1994).
  • the EcoRI adapters were then removed from the 3' end of the cDNA by digestion with NotI (Soares, 1994).
  • the cDNA was then ligated into the plasmid vector pBluescript II KS+ (Stratagene, La Jolla, California), and the ligated material was transformed into E.
  • coli host DH10B or DH12S by electroporation methods familiar to one skilled in the art (Soares, 1994). After growth overnight at 37°C, DNA was recovered from the E. coli colonies after scraping the plates by processing as directed for the Mega-prep kit (Qiagen, Chatsworth, California). The quality of the cDNA libraries was estimated by counting a portion of the total numbers of primary transformants and determining the average insert size and the percentage of plasmids with no cDNA insert. Additional cDNA libraries (human total brain, heart, kidney, leukocyte, and fetal brain) were purchased from Life Technologies, Bethesda, MD.
  • cDNA libraries both oligo (dT) and random hexamer (N 6 ) primed, were used for isolating cDNA clones transcribed within the HBM region: human bone, human brain, human kidney and human skeletal muscle (all cDNA libraries were made by the inventors, except for skeletal muscle (dT) and kidney (dT) cDNA libraries).
  • Four 10 x 10 arrays of each of the cDNA libraries were prepared as follows: the cDNA libraries were titered to 2.5 x 10 6 using primary transformants. The appropriate volume of frozen stock was used to inoculate 2 L of LB/ampicillin (100 mg/ml). This inoculated liquid culture was aliquotted into 400 tubes of 4 ml each.
  • Each tube contained approximately 5000 cfu.
  • the tubes were incubated at 30°C overnight with gentle agitation.
  • the cultures were grown to an OD of 0.7-0.9.
  • Frozen stocks were prepared for each of the cultures by aliquotting 100 ⁇ l of culture and 300 ⁇ l of 80% glycerol. Stocks were frozen in a dry ice/ethanol bath and stored at -70°C. The remaining culture was DNA prepared using the Qiagen (Chatsworth, CA) spin miniprep kit according to the manufacturer's instructions.
  • the DNAs from the 400 cultures were pooled to make 80 column and row pools.
  • the cDNA libraries were determined to contain HBM cDNA clones of interest by PCR. Markers were designed to amplify putative exons.
  • markers were used to screen the arrayed library. Positive addresses indicating the presence of cDNA clones were confirmed by a second PCR using the same markers.
  • a cDNA library was identified as likely to contain cDNA clones corresponding to a specific transcript of interest from the HBM region, it was manipulated to isolate the clone or clones containing cDNA inserts identical to the EST or direct-selected cDNA of interest. This was accomplished by a modification of the standard "colony screening" method ( Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY (1989 )). Specifically, twenty 150 mm LB+ampicillin agar plates were spread with 20,000 colony forming units (cfu) of cDNA library and the colonies allowed to grow overnight at 37°C.
  • Colonies were transferred to nylon filters (Hybond from Amersham, or equivalent) and duplicates prepared by pressing two filters together essentially as described ( Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY (1989 )). The "master" plate was then incubated an additional 6-8 hours to allow the colonies to grow back. The DNA from the bacterial colonies was then affixed to the nylon filters by treating the filters sequentially with denaturing solution (0.5 N NaOH, 1.5 M NaCl) for two minutes, neutralization solution (0.5 M Tris-Cl pH 8.0, 1.5,M NaCl) for two minutes (twice). The bacterial colonies were removed from the filters by washing in a solution of 2X SSC/0.1% SDS for one minute while rubbing with tissue paper. The filters were air dried and baked under vacuum at 80°C for 1-2 hours.
  • denaturing solution 0.5 N NaOH, 1.5 M NaCl
  • neutralization solution 0.5 M Tris-Cl pH 8.0, 1.5,M NaC
  • a cDNA hybridization probe was prepared by random hexamer labeling ( Fineberg and Vogelstein, Anal. Biochem., 132:6-13 (1983 )) or by including gene-specific primers and no random hexamers in the reaction (for small fragments). Specific activity was calculated and was >5X10 8 cpm/10 8 ⁇ g of cDNA. The colony membranes were then prewashed in 10 mM Tris-Cl pH 8.0, 1 M NaCl, 1 mM EDTA, 0.1% SDS for 30 minutes at 55 °C.
  • the filters were prehybridized in > 2 ml/filter of 6X SSC, 50 % deionized formamide, 2% SDS, 5X Denhardt's solution, and 100 mg/ml denatured salmon sperm DNA, at 42°C for 30 minutes.
  • the filters were then transferred to hybridization solution (6X SSC, 2% SDS, 5X Denhardt's, 100 mg/ml denatured salmon sperm DNA) containing denatured ⁇ 32 P-dCTP-labeled cDNA probe and incubated at 42°C for 16-18 hours.
  • the filters were washed under constant agitation in 2X SSC, 2% SDS at room temperature for 20 minutes, followed by two washes at 65°C for 15 minutes each. A second wash was performed in 0.5 X SSC, 0.5% SDS for 15 minutes at 65 °C. Filters were then wrapped in plastic wrap and exposed to radiographic film for several hours to overnight. After film development, individual colonies on plates were aligned with the autoradiograph so that they could be picked into a 1 ml solution of LB Broth containing ampicillin. After shaking at 37°C for 1-2 hours, aliquots of the solution were plated on 150 mm plates for secondary screening. Secondary screening was identical to primary screening (above) except that it was performed on plates containing ⁇ 250 colonies so that individual colonies could be clearly identified for picking.
  • the clones were characterized by restriction endonuclease cleavage, PCR, and direct sequencing to confirm the sequence identity between the original probe and the isolated clone.
  • the novel sequence from the end of the clone identified was used to probe the library again. This process was repeated until the length of the cDNA cloned matches that estimated to be full-length by the northern blot analysis.
  • RT-PCR was used as another method to isolate full length clones.
  • the cDNA was synthesized and amplified using a "Superscript One Step RT-PCR" kit (Life Technologies, Gaithersburg, MD). The procedure involved adding 1.5 ⁇ g of RNA to the following: 25 ⁇ l of reaction mix provided which is a proprietary buffer mix with MgSO 4 and dNTP's, 1 ⁇ l sense primer (10 ⁇ M) and 1 ⁇ l anti-sense primer (10 ⁇ M), 1 ⁇ l reverse transcriptase and Taq DNA polymerase mix provided and autoclaved water to a total reaction mix of 50 ⁇ l.
  • the reaction was then placed in a thermocycler for 1 cycle at 50°C for 15 to 30 minutes, then 94°C for 15 seconds, 55-60°C for 30 seconds and 68-72°C for 1 minute per kilobase of anticipated product and finally 1 cycle of 72°C for 5-10 minutes.
  • the sample was analyzed on an agarose gel.
  • the product was excised from the gel and purified from the gel (GeneClean, Bio 101).
  • the purified product was cloned in pCTNR (General Contractor DNA Cloning System, 5 Prime - 3 Prime, Inc.) and sequenced to verify that the clone was specific to the gene of interest.
  • Rapid Amplification of cDNA ends was performed following the manufacturer's instructions using a Marathon cDNA Amplification Kit (Clontech, Palo Alto, CA) as a method for cloning the 5' and 3' ends of candidate genes.
  • cDNA pools were prepared from total RNA by performing first strand synthesis, where a sample of total RNA sample was mixed with a modified oligo (dT) primer, heated to 70°C, cooled on ice and followed by the addition of: 5x first strand buffer, 10 mM dNTP mix, and AMV Reverse Transcriptase (20 U/ ⁇ l). The tube was incubated at 42°C for one hour and then the reaction tube was placed on ice.
  • dT modified oligo
  • Second strand synthesis the following components were added directly to the reaction tube: 5x second strand buffer, 10 mM dNTP mix, sterile water, 20x second strand enzyme cocktail and the reaction tube was incubated at 16°C for 1.5 hours. T4 DNA Polymerase was added to the reaction tube and incubated at 16°C for 45 minutes. The second-strand synthesis was terminated with the addition of an EDTA/Glycogen mix. The sample was subjected to a phenol/chloroform extraction and an ammonium acetate precipitation. The cDNA pools were checked for quality by analyzing on an agarose gel for size distribution. Marathon cDNA adapters (Clontech) were then ligated onto the cDNA ends.
  • the specific adapters contained priming sites that allowed for amplification of either 5' or 3' ends, depending on the orientation of the gene specific primer (GSP) that was chosen.
  • GSP gene specific primer
  • An aliquot of the double stranded cDNA was added to the following reagents: 10 ⁇ M Marathon cDNA adapter, 5x DNA ligation buffer, T4 DNA ligase. The reaction was incubated at 16°C overnight. The reaction was heat inactivated to terminate the reaction.
  • PCR was performed by the addition of the following to the diluted double stranded cDNA pool: 10x cDNA PCR reaction buffer, 10 ⁇ M dNTP mix, 10 ⁇ M GSP, 10 ⁇ M AP1 primer (kit), 50x Advantage cDNA Polymerase Mix.
  • Thermal Cycling conditions were 94 °C for 30 seconds, 5 cycles of 94°C for 5 seconds, 72 °C for 4 minutes, 5 cycles of 94°C for 5 seconds, 70°C for 4 minutes, 23 cycles of 94°C for 5 seconds, 68 °C for 4 minutes.
  • the RACE product was analyzed on an agarose gel and then excised and purified from the gel (GeneClean, BIO 101). The RACE product was then cloned into pCTNR (General Contractor DNA Cloning System, 5' - 3', Inc.) and the DNA sequence determined to verify that the clone is specific to the gene of interest.
  • Comparative genes were identified using the above procedures and the exons from each gene were subjected to mutation detection analysis. Comparative DNA sequencing was used to identify polymorphisms in HBM candidate genes from chromosome 11q12-13. DNA sequences for candidate genes were amplified from patient lymphoblastoid cell lines.
  • the inventors developed a method based on analysis of direct DNA sequencing of PCR products amplified from candidate regions to search for the causative polymorphism.
  • the procedure consisted of three stages that used different subsets of HBM family to find segregating polymorphisms and a population panel to assess the frequency of the polymorphisms.
  • the family resources result from a single founder leading to the assumption that all affected individuals will share the same causative polymorphism.
  • Candidate regions were first screened in a subset of the HBM family consisting of the proband, daughter, and her mother, father and brother. Monochromosomal reference sequences were produced concurrently and used for comparison. The mother and daughter carried the HBM polymorphism in this nuclear family, providing the ability to monitor polymorphism transmission. The net result is that two HBM chromosomes and six non-HBM chromosomes were screened. This allowed exclusion of numerous frequent alleles. Only alleles exclusively present in the affected individuals passed to the next level of analysis.
  • HBM pedigree Polymorphisms that segregated exclusively with the HBM phenotype in this original family were then re-examined in an extended portion of the HBM pedigree consisting of two additional nuclear families. These families consisted of five HBM and three unaffected individuals. The HBM individuals in this group included the two critical crossover individuals, providing the centromeric and telomeric boundaries of the critical region. Tracking the heredity of polymorphisms between these individuals and their affected parents allowed for further refining of the critical region. This group brought the total of HBM chromosomes screened to seven and the total of non-HBM chromosomes to seventeen.
  • PCR Polymerase chain reaction
  • the M13-21F (5'- GTA A CGA CGG CCA GT -3') (SEQ ID NO:30) and -28REV (5'- AAC AGC TAT GAC CAT G -3') (SEQ ID NO:31) primer binding sites were built on to the 5' end of each forward and reverse PCR primer, respectively, during synthesis.
  • 150 ng of genomic DNA was used in a 50 ⁇ l PCR with 2 U AmpliTaq, 500 nM primer and 125 ⁇ M dNTP. Buffer and cycling conditions were specific to each primer set.
  • TaqStart antibody (Clontech) was used for hot start PCR to minimize primer dimer formation. 10% of the product was examined on an agarose gel. The appropriate samples were diluted 1:25 with deionized water before sequencing.
  • Each PCR product was sequenced according to the standard Energy Transfer primer (Amersham) protocol. All reactions took place in 96 well trays. 4 separate reactions, one each for A, C, G and T were performed for each template. Each reaction included 2 ⁇ l of the sequencing reaction mix and 3 ⁇ l of diluted template. The plates were then heat sealed with foil tape and placed in a thermal cycler and cycled according to the manufacturer's recommendation. After cycling, the 4 reactions were pooled. 3 ⁇ l of the pooled product was transferred to a new 96 well plate and 1 ⁇ l of the manufacturer's loading dye was added to each well. All 96 well pipetting procedures occurred on a Hydra 96 pipetting station (Robbins Scientific, USA). 1 ⁇ l of pooled material was directly loaded onto a 48 lane gel running on an ABI 377 DNA sequencer for a 10 hour, 2.4 kV run.
  • Polyphred (University of Washington) was used to assemble sequence sets for viewing with Consed (University of Washington). Sequences were assembled in groups representing all relevant family members and controls for a specified target region. This was done separately for each of the three stages. Forward and reverse reads were included for each individual along with reads from the monochromosomal templates and a color annotated reference sequence. Polyphred indicated potential polymorphic sites with a purple flag. Two readers independently viewed each assembly and assessed the validity of the purple-flagged sites.
  • polymorphisms can also be present in SEQ ID NO:2. These is a change at position 2002 of SEQ ID NO:2. Either a guanine or an adenine can appear at this position. This polymorphism is silent and is not associated with any change in the amino acid sequence.
  • the second change is at position 4059 of SEQ ID NO:2 corresponding in a cytosine (C) to thymine (T) change. This polymorphism results in a corresponding amino acid change from a valine (V) to an alanine (A).
  • Other polymorphisms were found in the candidate gene exons and adjacent intron sequences. Any one or combination of the polymorphisms listed in Table 4 or the two discussed above could also have a minor effect on bone mass when present in SEQ ID NO:2.
  • the present invention encompasses the nucleic acid sequences having the nucleic acid sequence of SEQ ID NO: 1 with the above-identified point mutations.
  • the present invention encompasses the nucleic acid of SEQ ID NO: 2.
  • a base-pair substitution changing G to T at position 582 in the coding sequence of Zmax1 was identified as heterozygous in all HBM individuals, and not found in the unaffected individuals (i.e., b527d12-h_Contig087C_1.nt).
  • Fig. 5 shows the order of the contigs in B527D12. The direction of transcription for the HBM gene is from left to right.
  • the sequence of contig308G of B527D12 is the reverse complement of the coding region to the HBM gene.
  • the relative polymorphism in contig 308G shown in Table 4 as a base change substitution of C to A is the complement to the G to T substitution in the HBM gene.
  • This mutation causes a substitution of glycine 171 with valine (G171V).
  • the amplicon containing the HBM1 polymorphism was PCR amplified using primers specific for the exon of interest.
  • the appropriate population of individuals was PCR amplified in 96 well microtiter plates as follows. PCR reactions (20 ⁇ l) containing 1X Promega PCR buffer (Cat.
  • the allele specific oligonucleotides were designed with the polymorphism approximately in the middle. Oligonucleotides were phosphate free at the 5' end and were purchased from Gibco BRL. Sequences of the oligonucleotides are:
  • Blots were prehybridized in 10 ml 5X SSPE, 5X Denhardt's, 2% SDS, and 100 ⁇ g/ml, denatured, sonicated salmon sperm DNA at 40°C for 2 hr. The entire reaction mix of kinased oligo was then added to 10 ml fresh hybridization buffer (5X SSPE, 5X Denhardt's, 2% SDS) and hybridized at 40°C for at least 4 hours to overnight.
  • 5X SSPE 5X Denhardt's, 2% SDS
  • the two films that best captured the allele specific assay with the 2 ASOs were converted into digital images by scanning them into Adobe PhotoShop. These images were overlaid against each other in Graphic Converter and then scored and stored in FileMaker Pro 4.0 (see Fig. 9 ).
  • HBM1 allele frequency in ethnically diverse populations 672 random individuals from various ethnic groups were typed by the allele specific oligonucleotide (ASO) method. This population included 96 CEPH grandparents (primarily Caucasian), 192 Caucasian, 192 African-American, 96 Hispanic, and 96 Asian individuals. No evidence was obtained for the presence of the HBM1 polymorphism in any of these individuals. Overall, a total of 911 individuals were typed either by direct sequencing or ASO hybridization; all were homozygous GG at the site of the HBM polymorphism ( Fig. 14 ). This information illustrates that the HBM1 allele is rare in various ethnic populations.
  • ASO allele specific oligonucleotide
  • this invention provides a rapid method of identifying individuals with the HBM1 allele. This method could be used in the area of diagnostics and screening of an individual for susceptibility to osteoporosis or other bone disorder.
  • the assay could also be used to identify additional individuals with the HBM1 allele or the additional polymorphisms described herein.
  • gene expression by non-isotopic in situ hybridization was performed as follows, but other methods would be known to the skilled artisan.
  • Tibias were collected from two 6 to 8 week old female Sprague Dawley rats euthanized by carbon dioxide asphyxiation. Distal ends were removed and proximal tibias were snap frozen in OCT embedding medium with liquid nitrogen immediately following death. Tissues were stored in a -80°C freezer.
  • Probes for amplifying PCR products from cDNA were prepared as follows.
  • the primers to amplify PCR products from a cDNA clone were chosen using published sequences of both human LRP5 (Genbank Accession No. ABO17498) and mouse LRP5 (Genbank Accession No. AFO64984).
  • the PCR products were derived from an intracellular portion of the protein coding region.
  • PCR was performed in a 50 ⁇ l reaction volume using cDNA clone as template. PCR reactions contained 1.5 mM MgCl 2 , 1 unit Amplitaq, 200 ⁇ M dNTPs and 2 ⁇ M each primer.
  • PCR cycling conditions were 94°C for 1 min., followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds; followed by a 5 minute extension at 72°C.
  • the reactions were then run on a 1.5% agarose Tris-Acetate gel. DNA was eluted from the agarose, ethanol precipitated and resuspended in 10 mM Tris, pH 8.0. Gel purified PCR products were prepared for both mouse and human cDNAs and supplied to Pathology Associates International for in situ hybridizations.
  • Riboprobes were synthesized as follows. The PCR products were reamplified with chimeric primers designed to incorporate either a T3 promoter upstream, or a T7 promoter downstream of the reamplification products. The resulting PCR products were used as template to synthesize digoxigenin-labeled riboprobes by in vitro transcription (IVT). Antisense and sense riboprobes were synthesized using T7 and T3 RNA polymerases, respectively, in the presence of digoxigenin-11-UTP (Boehringer-Mannheim) using a MAXIscript IVT kit (Ambion) according to the manufacturer.
  • Riboprobe integrity was assessed by electrophoresis through a denaturing polyacrylamide gel. Molecular size was compared with the electrophoretic mobility of a 100-1000 base pair (bp) RNA ladder (Ambion). Probe yield and labeling was evaluated by blot immunochemistry. Riboprobes were stored in 5 ⁇ l aliquots at -80°C.
  • the in situ hybridization was performed as follows. Frozen rat bone was cut into 5 ⁇ M sections on a Jung CM3000 cryostat (Leica) and mounted on adhesive slides (Instrumedics). Sections were kept in the cryostat at 20°C until all the slides were prepared in order to prevent mRNA degradation prior to post-fixation for 15 minutes in 4% paraformaldehyde. Following post-fixation, sections were incubated with 1 ng/ ⁇ l of either antisense or sense riboprobe in Pathology Associates International (PAI) customized hybridization buffer for approximately 40 hours at 58°C. Following hybridization, slides were subjected to a series of post-hybridization stringency washes to reduce nonspecific probe binding.
  • PAI Pathology Associates International
  • Hybridization was visualized by immunohistochemistry with an anti-digoxigenin antibody (FAB fragment) conjugated to alkaline phosphatase.
  • FAB fragment anti-digoxigenin antibody conjugated to alkaline phosphatase.
  • Hybridization for Zmax1 was primarily detected in areas of bone involved in remodeling, including the endosteum and trabecular bone within the metaphysis. Hybridization in selected bone lining cells of the periosteum and epiphysis were also observed. Positive signal was also noted in chondrocytes within the growth plate, particularly in the proliferating chondrocytes. See Figs. 10 , 11 and 12 for representative photomicrographs of in situ hybridization results.
  • Zmax1 is involved in the process of bone growth and mineralization.
  • the activity and differentiation of osteoblasts and osteoclasts are closely coordinated during development as bone is formed and during growth as well as in adult life as bone undergoes continuous remodeling.
  • the formation of internal bone structures and bone remodeling result from the coupling of bone resorption by activated osteoclasts with subsequent deposition of new material by osteoblasts.
  • Zmax1 is related to the LDL receptor gene, and thus may be a receptor involved in mechanosensation and subsequent signaling in the process of bone remodeling. Therefore, changes in the level of expression of this gene could impact on the rate of remodeling and degree of mineralization of bone.
  • Antisense oligonucleotides are short synthetic nucleic acids that contain complementary base sequences to a targeted RNA. Hybridization of the RNA in living cells with the antisense oligonucleotide interferes with RNA function and ultimately blocks protein expression. Therefore, any gene for which the partial sequence is known can be targeted by an antisense oligonucleotide.
  • Antisense technology is becoming a widely used research tool and will play an increasingly important role in the validation and elucidation of therapeutic targets identified by genomic sequencing efforts.
  • Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA that encodes the target gene.
  • oligonucleotide complementary to the mRNA that encodes the target gene There are several possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of inhibition of protein function. This technique was originally used to elucidate the function of a target gene, but may also have therapeutic applications, provided it is designed carefully and properly.
  • An example of materials and methods for preparing antisense oligonucleotides can be performed as follows. Preliminary studies have been undertaken in collaboration with Sequiter (Natick, MA) using the antisense technology in the osteoblast-like murine cell line, MC3T3. These cells can be triggered to develop along the bone differentiation sequence. An initial proliferation period is characterized by minimal expression of differentiation markers and initial synthesis of collagenous extracellular matrix. Collagen matrix synthesis is required for subsequent induction of differentiation markers. Once the matrix synthesis begins, osteoblast marker genes are activated in a clear temporal sequence: alkaline phosphatase is induced at early times while bone sialoprotien and osteocalcin appear later in the differentiation process.
  • Matrix mineralization which does not begin until several days after maturation has started, involves deposition of mineral on and within collagen fibrils deep within the matrix near the cell layer-culture plate interface.
  • the collagen fibril-associated mineral formed by cultured osteoblasts resembles that found in woven bone in vivo and therefore is used frequently as a study reagent.
  • MC3T3 cells were transfected with antisense oligonucleotides for the first week of the differentiation, according to the manufacturer's specifications ( U.S. Patent No. 5,849,902 ).
  • oligonucleotides designed for Zmax1 are given below:
  • yeast two hybrid protein interaction technology was utilized. This technique facilitates the identification of proteins that interact with one another by coupling tester proteins to components of a yeast transcription system ( Fields and Song, 1989, Nature 340: 245-246 ; U.S. Pat. No. 5,283,173 by Fields and Song ; Johnston, 1987, Microbiol. Rev. 51: 458-476 ; Keegan et al, 1986, Science 231: 699-704 ; Durfee et al, 1993, Genes Dev. 7: 555-569 ; Chien et al, 1991, Proc. Natl. Acad.
  • a "bait" protein the protein for which one seeks interacting proteins, is fused to the DNA binding domain of a yeast transcription factor.
  • a cDNA library is constructed that contains cDNAs fused to the transcriptional activation domain of the same yeast transcription factor; this is termed the prey library.
  • the bait construct and prey library are transformed into yeast cells and then mated to produce diploid cells. If the bait interacts with a specific prey from the cDNA library, the activation domain is brought into the vicinity of the promoter via this interaction. Transcription is then driven through selectable marker genes and growth on selective media indicates the presence of interacting proteins.
  • amino acid sequence used in the yeast two hybrid experiments discussed herein consisted of the entire cytoplasmic domain and a portion of the transmembrane domain and is shown below (amino to carboxy orientation):
  • the last 6 amino acids of the putative transmembrane domain are indicated in bold. Putative SH3 domains are underlined. Additional amino acid sequences of 50 amino acids or greater in either the proteins encoded by the Zmax1 or HBM alleles can also be used as bait. The upper size of the polypeptide used as bait is limited only by the presence of a complete transmembrane domain (see Fig. 4 ), which will render the bait to be nonfunctional in a yeast two hybrid system. These additional bait proteins can be used to identify additional proteins which interact with the proteins encoded by HBM or Zmax1 in the focal adhesion signaling pathway or in other pathways in which these HBM or Zmax1 proteins may act. Once identified, methods of identifying agents which regulate the proteins in the focal adhesion signaling pathway or other pathways in which HBM acts can be performed as described herein for the HBM and Zmax1 proteins.
  • the cytoplasmic domain of Zmax1 was subcloned into two bait vectors.
  • the first vector was pDBleu, which was used to screen a brain, and Hela prey cDNA library cloned into the vector pPC86 (Clontech).
  • the second bait vector used was pDBtrp, which was used to screen a cDNA prey library derived from the TE85 osteosarcoma cell line in vector pOP46. Standard techniques known to those skilled in the art were used as described in Fields and Song, 1989, Nature 340: 245-246 ; U.S. Pat. No. 5,283,173 by Fields and Song ; Johnston, 1987, Microbiol. Rev.
  • an overnight culture of the bait yeast strain was grown in 20 ml SD selective medium with 2% glucose (pDBLeu, SD -Leu medium, pDBtrp, SD -trp medium). The cultures were shaken vigorously at 30°C overnight. The cultures were diluted 1 : 10 with complete medium (YEPD with 2% glucose) and the cultures then incubated with shaking for 2 hrs at 30°C.
  • the frozen prey library was thawed, and the yeast cells reactivated by growing them in 150 ml YEPD medium with 2% glucose for 2 hrs at 30°C.
  • a filter unit was sterilized with 70% ethanol and washed with sterile water to remove the ethanol.
  • the cell densities of both bait and prey cultures were measured by determining the OD at 600 nm.
  • the filter was then transferred onto a prewarmed YEPD agar plate with the cell side up, removing all air bubbles underneath the filter. Plates were then incubated at 30 °C for 6 hrs.
  • One filter was transferred into a 50 ml Falcon tube, and 10 ml of SD with 2% Glucose was added; cells were resuspended by vortexing for 10 sec.
  • the number of primary diploid cells (growth on SD -Leu, -Trp plates) versus the numbers of colony forming units growing on SD -Trp and SD -Leu plates only was then titered. Different dilutions were plated and incubated at 30°C for two days. The number of colony forming units was then counted. The number of diploid colonies (colonies on SD -Leu -Trp plates) permits the calculation of whether or not the whole library of prey constructs was mated to the yeast expressing the bait. This information is important to judge the quality of the screen.
  • Resuspended cells from 5 filtermatings were then pooled and the cells sedimented by centrifugation in a 50 ml Falcon tube. Cells were then resuspended in 16 ml SD medium with 2% Glc. Two ml of this cell suspension was plated onto 8 square plates each (SD -Leu, -Trp) with sterile glass beads and selected for diploid cells by incubating at 30°C for 18 - 20 hrs.
  • yeast cells were then spread homogeneously with sterile glass beads and incubated at 30°C for 4 days.
  • the number of colony forming yeast cells was titered by plating different dilutions of the scraped cell suspension onto SD -Leu, -Trp plates. Usually, plating of 100 ⁇ l of a 10 -3 and 10 -4 dilution gave 100 -1000 colonies per plate.
  • Yeast cells from an isolated colony were picked with a sterile tooth pick and transferred into individual wells of a 96 well plate.
  • the cells were resuspended in 50 ⁇ l of SD -Leu, -Trp, -His medium and incubated at 30°C for one day.
  • the yeast cells were then stamped onto a SD -Leu, -Trp, -His plate in 96 well format and incubated at 30°C for 2 days.
  • Yeast cells were also stamped onto a Nylon filter covering a YEPD plate and incubated at 30°C for one day. The cells on the Nylon filter were used for the analysis of the ⁇ - Gal reporter activity.
  • Yeast colonies were scraped from the SD -Leu, -Trp, -His plate with a sterile tooth pick, and reconfigured, if necessary, according to the ⁇ - Gal activity and then resuspended in 20 % glycerol. This served as a master plate for storage at -80°C.
  • yeast cells from the glycerol stock were stamped onto a SD -Trp plate and incubated at 30°C for 2 days. After two days of incubation, the yeast colonies were ready for colony PCR and sequencing. Standard colony PCR conditions were used to amplify inserts from preys recovered from the interaction screen. Sequencing was done using standard sequencing reactions and ABI377 (Perkin Elmer) fluorescent sequencing machines.
  • Glycerol stocks of the prey of interest were thawed and inoculated in a 10 ml overnight culture of SD with glucose -Trp. After overnight growth, plasmid DNA preparation was performed using the BIO 101 RPM Yeast Plasmid Isolation Kit with 10 ml of culture. The culture was centrifuged and transfered to a 1.5 ml microcentrifuge tube. Yeast Lysis Matrix was then added to the pellet followed by 250 ⁇ l of Alkaline Lysis Solution. Samples were then vortexed for 5 minutes. 250 ⁇ l Neutralizing Solution was added and the sample mixed briefly. Samples were centrifuged for 2 minutes at room temperature in a microcentrifuge.
  • the supernatant was transferred to a Spin Filter avoiding debris and Lysis Matrix. 250 ⁇ l of Glassmilk Spin Buffer was added, and the tubes inverted to mix. Samples were centrifuged for 1 min and the liquid in the Catch Tube was discarded. 500 ⁇ l of Wash Solution was added, the samples were centrifuged for 1 min, and the wash solution was discarded. The wash step was repeated once followed by a 1 min dry centrifugation to drive the remaining liquid out of the Spin Filter. The filter was transferred to a new Catch Tube and 100 ⁇ l of sterile H 2 O was added; samples were then vortexed briefly to resuspend and centrifuged for 30 seconds to collect the DNA in the bottom of the Catch Tube.
  • Miniprep DNA was prepared using the Qiagen QIAprep Spin Miniprep Kit. DNA was finally eluted with 30 ⁇ l of Qiagen EB buffer. One ⁇ l of the plasmid DNA samples was then used to transform yeast cells using standard procedures. After 2 days of growth on SD -trp media, colonies were picked and patched onto fresh media. Similarly, bait colonies were patched onto SD -Leu media. Both were grown overnight at 30°C.
  • colonies were placed in a 96 well dish with 200 ⁇ l of SD-medium, leaving wells 1 and 96 blank.
  • Ten microliters from the first 96 well dish was plated into another flat bottom 96 well dish containing 100 ⁇ l of SD-medium.
  • Controls consisted of a negative control and a very weak positive control.
  • the cell density was measured at OD 600 (a value of 1 corresponds to 1x10 7 cells utilizing a 96 well spectrophotometer). The OD was usually between 0.03 and 0.10.
  • 50 ⁇ l of reaction mixture were pipetted into each well. Fifty microliters of culture were then added and mixed by pipetting up and down twice. The reaction was incubated for 30 minutes at room temperature followed by measurement of Relative Light Units using a luminometer.
  • Table 6 lists the genes identified in the yeast two hybrid screens from the 3 prey libraries tested. Two genes, zyxin and axin, were found to interact with the cytoplasmic domain of Zmax1 in all three screens. Three genes, alpha-actinin, TCB and S1-5 interacted in two of the three screens.
  • PINCH is a LIM domain-containing protein that is known to interact with integrin-linked kinase, an early signaler in integrin and growth factor signaling pathways. The finding of a closely related gene in the yeast two hybrid screen raises the possibility of a novel pathway linked to integrin signaling from extracellular matrix signals.
  • Trio also known to localize to focal adhesions, is thought to play a key role in coordinating cell-matrix interactions and cytoskeletal rearrangements involved in cell movement.
  • Zyxin another LIM domain-containing protein, is also localized to adhesion plaques and is thought to be involved in reorganization of the cytoskeleton when triggers are transmitted via integrin signaling pathways.
  • Zyxin also interacts with alpha actinin, which we identified as interacting with Zmax1.
  • Other LIM domain containing proteins identified include the human homologue of mouse ajuba, LIMD1, and a novel LIMD1-like protein.
  • Axin was also identified from the two hybrid experiments. This protein is involved in inhibition of the Wnt signaling pathway and interacts with the tumor suppressor APC. There is a link here with the focal adhesion signaling described above: one common step in the two pathways involves inhibition of glycogen synthase kinase 3, which in turn results in the activation of ⁇ -catenin/Lef-1 and AP-1 transcription factors. Axin/APC are involved in this as well as integrin linked kinase.
  • the Wnt pathway has a role in determining cell fates during embryogenesis. If inappropriately activated, the Wnt pathway may also lead to cancer. The Wnt pathway also seems to have a role in cytoskeletal rearrangements.
  • a model depicting Zmax1 involvement in focal adhesion signaling is depicted in Fig. 15 .
  • Another aspect contemplated by the invention would be to regulate bone density and bone mass disorders by the regulating focal adhesion signaling.
  • the regulation can occur by regulating the DNA, mRNA transcript or protein encoded by any of the members involved in the focal adhesion signaling pathway as identified by the yeast two hybrid system.
  • novel nucleic acids and proteins identified by the HBM. yeast two hybrid system include but are not limited to SEQ ID NO: 66 (Ajuba), SEQ ID NO: 71 (a gene similar to a gene encoding LIM domains containing protein 1), SEQ ID NO: 77 (Glu-Lys Rich protein), SEQ ID NO: 79 (PINCH-like gene), SEQ ID NO: 90 (Ajuba protein), SEQ ID NO: 93 (protein similar to TRIO), SEQ ID NO: 94 0, SEQ ID NO: 99 (Glu-Lys rich protein) and SEQ ID NO: 102 (PINCH-like protein).
  • the protein encoded by Zmax1 is related to the Low Density Lipoprotein receptor (LDL receptor).
  • LDL receptor Low Density Lipoprotein receptor
  • the LDL receptor is responsible for uptake of low density lipoprotein, a lipid-protein aggregate that includes cholesterol.
  • Individuals with a defect in the LDL receptor are deficient in cholesterol removal and tend to develop artherosclerosis.
  • cells with a defective LDL receptor show increased production of cholesterol, in part because of altered feedback regulation of cholesterol synthetic enzymes and in part because of increased transcription of the genes for these enzymes.
  • cholesterol is a precursor for the formation of steroid hormones.
  • the LDL receptor may, directly or indirectly, function as a signal transduction protein and may regulate gene expression. Because Zmax1 is related to the LDL receptor, this protein may also be involved in signaling between cells in a way that affects bone remodeling.
  • the glycine 171 amino acid is likely to be important for the function of Zmax1 because this amino acid is also found in the mouse homologue of Zmax1.
  • the closely related LRP6 protein also contains glycine at the corresponding position ( Brown et al, Biochemical and Biophysical Research Comm., 248:879-888 (1988 )). Amino acids that are important in a protein's structure or function tend to be conserved between species, because natural selection prevents mutations with altered amino acids at important positions from arising.
  • the extracellular domain of Zmax1 contains four repeats consisting of five YWTD motifs followed by an EFG motif.
  • This 5YWTD+EGF repeat is likely to form a distinct folded protein domain, as this repeat is also found in the LDL receptor and other LDL receptor-related proteins.
  • the first three 5YWTD+EGF repeats are very similar in their structure, while the fourth is highly divergent.
  • Glycine 171 occurs in the central YWTD motif of the first 5YWTD+EGF repeat in Zmax1.
  • the other two similar 5YWTD+EGF repeats of Zmax1 also contain glycine at the corresponding position, as does the 5YWTD+EGF repeat in the LDL receptor protein.
  • Figs. 7A-B Northern blot analysis reveals that Zmax1 is expressed in human bone tissue as well as numerous other tissues.
  • a multiple-tissue Northern blot (Clontech, Palo Alto, CA) was probed with exons from Zmax1.
  • the 5.5 kb Zmax1 transcript was highly expressed in heart, kidney, lung, liver and pancreas and is expressed at lower levels in skeletal muscle and brain.
  • a second northern blot, shown in Fig. 7B confirmed the transcript size at 5.5 kb, and indicated that Zmax1 is expressed in bone, bone marrow, calvaria and human osteoblastic cell lines.
  • these results coupled with the yeast two hybrid results indicate that the HBM polymorphism in the Zmax1 gene is responsible for the HBM phenotype, and that the Zmax1 gene is important in bone development.
  • molecules that bind to Zmax1 may usefully alter bone development.
  • Such molecules may include, for example, small molecules, proteins, RNA aptamers, peptide aptamers, and the like.
  • nucleic acids of the present invention may be produced by replication in a suitable host cell. Natural or synthetic nucleic acid fragments coding for a desired fragment will be incorporated into recombinant nucleic acid constructs, usually DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the nucleic acid constructs will be suitable for replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to (with and without integration within the genome) cultured mammalian or plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention is described, for example, in Sambrook et al, Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989 ) or Ausubel et al, Current Protocols in Molecular Biology, J. Wiley and Sons, NY (1992 ).
  • the nucleic acids of the present invention may also be produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage et al, Tetra. Letts., 22:1859-1862 (1981 ) or the triester method according to Matteucci,et al, J. Am. Chem. Soc., 103:3185 (1981 ), and may be performed on commercial, automated oligonucleotide synthesizers.
  • a double-stranded fragment may be obtained from the single-stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
  • Nucleic acid constructs prepared for introduction into a prokaryotic or eukaryotic host cell may comprise a replication system recognized by the host, including the intended nucleic acid fragment encoding the desired protein, and will preferably also include transcription and translational initiation regulatory sequences operably linked to the protein encoding segment.
  • Expression vectors may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences.
  • ARS origin of replication or autonomously replicating sequence
  • Secretion signals may also be included where appropriate, whether from a native HBM or Zmax1 protein or from other receptors or from secreted proteins of the same or related species, which allow the protein to cross and/or lodge in cell membranes, and thus attain its functional topology, or be secreted from the cell.
  • Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al, Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989 ) or Ausubel et al, Current Protocols in Molecular Biology, J. Wiley and Sons, NY (1992 ).
  • An appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host cell, and may include, when appropriate, those naturally associated with Zmax1 or HBM genes.
  • Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al, Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989 ) or Ausubel et al, Current Protocols in Molecular Biology, J. Wiley and Sons, NY (1992 ). Many useful vectors are known in the art and may be obtained from such vendors as Stratagene, New England BioLabs, Promega Biotech, and others.
  • Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts.
  • Useful yeast promoters include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others.
  • Vectors and promoters suitable for use in yeast expression are further described in EP 73,675A .
  • Non-native mammalian promoters might include the early and late promoters from SV40 ( Fiers et al, Nature, 273:113 (1978 )) or promoters derived from murine Moloney leukemia virus, mouse tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma.
  • the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made.
  • amplifiable gene e.g., DHFR
  • expression vectors may replicate autonomously, they may also replicate by being inserted into the genome of the host cell, by methods well known in the art.
  • Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene ensures growth of only those host cells which express the inserts.
  • Typical selection genes encode proteins that a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; b) complement auxotrophic deficiencies, or c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • the choice of the proper selectable marker will depend on the host cell, and appropriate markers for different host cells are well known in the art.
  • the vectors containing the nucleic acids of interest can be transcribed in vitro , and the resulting RNA introduced into the host cell by well-known methods, e.g., by injection (see, Kubo et al, FEBS Letts. 241:119 (1989 )), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods.
  • nucleic acids into the host cell by any method known in the art, including those described above, will be referred to herein as "transformation.”
  • transformation The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.
  • nucleic acids and proteins of the present invention may be prepared by expressing the HBM nucleic acid or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells.
  • prokaryotic hosts are strains of Escherichia coli , although other prokaryotes, such as Bacillus subtilis or Pseudomonas may also be used.
  • Mammalian or other eukaryotic host cells such as those of yeast, filamentous fungi, plant, insect, or amphibian or avian species, may also be useful for production of the proteins of the present invention. Propagation of mammalian cells in culture is per se well known. See, Jakoby and Pastan (eds.), Cell Culture. Methods in Enzymology, volume 58, Academic Press, Inc., Harcourt Brace Jovanovich, NY, (1979 )).
  • Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38, BHK, and COS cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g., to provide higher expression desirable glycosylation patterns, or other features.
  • Clones are selected by using markers depending on the mode of the vector construction.
  • the marker may be on the same or a different DNA molecule, preferably the same DNA molecule.
  • the transformant may be selected, e.g., by resistance to ampicillin, tetracycline or other antibiotics. Production of a particular product based on temperature sensitivity may also serve as an appropriate marker.
  • Prokaryotic or eukaryotic cells transformed with the nucleic acids of the present invention will be useful not only for the production of the nucleic acids and proteins of the present invention, but also, for example, in studying the characteristics of Zmax1 or HBM proteins.
  • Antisense nucleic acid sequences arc useful in preventing or diminishing the expression of Zmax1 or HBM, as will be appreciated by one skilled in the art.
  • nucleic acid vectors containing all or a portion of the Zmax1 or HBM gene or other sequences from the Zmax1 or HBM region may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell will interfere with Zmax1 or HBM transcription and/or translation and/or replication.
  • the probes and primers based on the Zmax1 and HBM gene sequences disclosed herein are used to identify homologous Zmax1 and HBM gene sequences and proteins in other species. These Zmax1 and HBM gene sequences and proteins are used in the diagnostic/prognostic, therapeutic and drug screening methods described herein for the species from which they have been isolated.
  • HBM protein of the invention can be performed essentially as outlined below, To facilitate the cloning, expression and purification of membrane and secreted protein from the HBM gene, a gene expression system, such as the pET System (Novagen), for cloning and expression of recombinant proteins in E. coli was selected. Also, a DNA sequence encoding a peptide tag, the His-Tap, was fused to the 3' end of DNA sequences of interest to facilitate purification of the recombinant protein products. The 3' end was selected for fusion to avoid alteration of any 5 terminal signal sequence.
  • pET System Novagen
  • Nucleic acids chosen, for example, from the nucleic acids set forth in SEQ , ID NOS: 1, 3 and 5-12 for cloning HBM were prepared by polymerase chain reaction (PCR).
  • Synthetic oligonucleotide primers specific for the 5' and 3' ends of the HBM nucleotide sequence were designed and purchased from Life Technologies (Gaithersburg, MD). All forward primers (specific for the 5' end of the sequence) were designed to include an NcoI cloning site at the 5' terminus. These primers were designed to permit initiation of protein translation at the methionine residue encoded within the NcoI site followed by a valine residue and the protein encoded by the HBM DNA sequence.
  • All reverse primers included an EcoRI site at the 5' terminus to permit cloning of the HBM sequence into the reading frame of the pET-28b.
  • the pET-28b vector provided a sequence encoding an additional 20 carboxyl-teminal amino acids including six histidine residues (at the C-terminus), which comprised the histidine affinity tag.
  • Genomic DNA prepared from the HBM gene was used as the source of template DNA for PCR amplification ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons (1994 )).
  • genomic DNA 50 ng was introduced into a reaction vial containing 2 mM MgCl 2 , 1 ⁇ M synthetic oligonucleotide primers (forward and reverse primers) complementary to and flanking a defined HBM, 0.2 mM of each of deoxynucleotide triphosphate, dATP, dGTP, dCTP, dTTP and 2.5 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ) in a final volume of 100 microliters.
  • each sample of amplified DNA was purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD). All amplified DNA samples were subjected to digestion with the restriction endonucleases, e.g., NcoI and EcoRI (New England BioLabs, Beverly, MA) ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994 )). DNA samples were then subjected to electrophoresis on 1.0% NuSeive (FMC BioProducts, Rockland, ME) agarose gels. DNA was visualized by exposure to ethidium bromide and long wave UV irradiation. DNA contained in slices isolated from the agarose gel was purified using the Bio 101 GeneClean Kit protocol (Bio 101, Vista, CA).
  • the restriction endonucleases e.g., NcoI and EcoRI (New England BioLabs, Beverly, MA) ( Ausubel et al, Current Protocols in
  • the pET-28b vector was prepared for cloning by digestion with restriction endonucleases, e.g., NcoI and EcoRI (New England BioLabs, Beverly, MA) ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994 )).
  • restriction endonucleases e.g., NcoI and EcoRI (New England BioLabs, Beverly, MA) ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994 )
  • the pET-28a vector which encodes the histidine affinity tag that can be fused to the 5' end of an inserted gene, was prepared by digestion with appropriate restriction endonucleases.
  • Competent bacteria E. coli strain BL21 or E. coli strain BL21 (DE3), were transformed with recombinant pET expression plasmids carrying the cloned HBM sequence according to standard methods ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994 )).
  • ligation reaction was mixed with 50 ⁇ l of electrocompetent cells and subjected to a high voltage pulse, after which samples were incubated in 0.45 ml SOC medium (0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM KCI, 10 mM MgCl 2 , 10 mM MgS0 4 and 20 mM glucose) at 37°C with shaking for 1 hour. Samples were then spread on LB agar plates containing 25 ⁇ g/ml kanamycin sulfate for growth overnight. Transformed colonies of BL21 were then picked and analyzed to evaluate cloned inserts, as described below.
  • SOC medium 0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM KCI, 10 mM MgCl 2 , 10 mM MgS0 4 and 20 mM glucose
  • the pET vector can be propagated in any E. coli K-12 strain, e.g., HMS 174, HB101, JM109, DH5 and the like, for purposes of cloning or plasmid preparation.
  • Hosts for expression include E. coli strains containing a chromosomal copy of the gene for T7 RNA polymerase. These hosts were lysogens of bacteriophage DE3, a lambda derivative that carries the ladI gene, the lacUV5 promoter and the gene for T7 RNA polymerase.
  • T7 RNA polymerase was induced by addition of isopropyl- ⁇ -D-thiogalactoside (IPTG), and the T7 RNA polymerase transcribes any target plasmid containing a functional T7 promoter, such as pET-28b, carrying its gene of interest.
  • Strains include, for example, BL21(DE3) ( Studier et al, Meth. Enzymol., 185:60-89 (1990 )).
  • plasmid DNA 50 ng of plasmid DNA are isolated as described above to transform competent BL21(DE3) bacteria as described above (provided by Novagen as part of the pET expression kit).
  • the lacZ gene ⁇ -galactosidase
  • the lacZ gene is expressed in the pET-System as described for the HBM recombinant constructions.
  • Transformed cells were cultured in SOC medium for 1 hour, and the culture was then plated on LB plates containing 25 ⁇ g/ml kanamycin sulfate.
  • the bacterial colonies were pooled and grown in LB medium containing kanamycin sulfate (25 ⁇ g/ml) to an optical density at 600 nM of 0.5 to 1.0 O.D. units, at which point 1 mM IPTG was added to the culture for 3 hours to induce gene expression of the HBM recombinant DNA constructions.
  • the frozen cells can be thawed, resuspended in buffer and ruptured by several passages through a small volume microfluidizer (Model M-110S, Microfluidics International Corp., Newton, MA).
  • the resultant homogenate is centrifuged to yield a clear supernatant (crude extract) and, following filtration, the crude extract is fractioned over columns. Fractions are monitored by absorbance at OD 280 nm and peak fractions may be analyzed by SDS-PAGE.
  • concentrations of purified protein preparations are quantified spectrophotometrically using absorbance coefficients calculated from amino acid content ( Perkins, Eur. J. Biochem., 157:169-180 (1986 )). Protein concentrations are also measured by the method of Bradford, Anal. Biochem., 72:248-254 (1976 ) and Lowry et al, J. Biol. Chem., 193:265-275 (1951 ) using bovine serum albumin as a standard.
  • SDS-polyacrylamide gels of various concentrations were purchased from BioRad (Hercules, CA), and stained with Coomassie blue.
  • Molecular weight markers may include rabbit skeletal muscle myosin (200 kDa), E. coli ⁇ -galactosidase (116 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anyhdrase (31 kDa), soybean trypsin inhibitor (21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa).
  • antibodies specific for binding may be either polyclonal or monoclonal, and may be produced by in vitro or in vivo techniques well known in the art.
  • Monoclonal antibodies to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas ( Kohler, Nature, 256:495 (1975 )).
  • a mouse is inoculated with a few micrograms of HBM protein over a period of two weeks. The mouse is then sacrificed. The cells that produce antibodies are then removed from the mouse's spleen.
  • the spleen cells are then fused with polyethylene glycol with mouse myeloma cells.
  • the successfully fused cells are diluted in a microtiter plate and growth of the culture is continued.
  • the amount of antibody per well is measured by immunoassay methods such as ELISA ( Engvall, Meth. Enzymol., 70:419 (1980 )).
  • Clones producing antibody can be expanded and further propagated to produce HBM antibodies.
  • Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides, or alternatively, to selection of libraries of antibodies in phage or similar vectors. See Huse et al, Science, 246:1275-1281 (1989 ). For additional information on antibody production see Davis et al, Basic Methods in Molecular Biology, Elsevier, NY, Section 21-2 (1989 ).
  • Gene therapy can be defined as the deliberate transfer of DNA for therapeutic purposes. Improvement in gene transfer methods has allowed for development of gene therapy protocols for the treatment of diverse types of diseases. Gene therapy has also taken advantage of recent advances in the identification of new therapeutic genes, improvement in both viral and nonviral gene delivery systems, better understanding of gene regulation, and improvement in cell isolation and transplantation.
  • HBM function The bone mass elevating activity of the HBM. gene is termed "HBM function.”
  • a method is also provided of supplying HBM function to mesenchymal stem cells ( Onyia et al, J. Bone Miner. Res., 13:20-30 (1998 ); Ko et al, Cancer Res., 56:4614-4619 (1996 )). Supplying such a function provides protection against osteoporosis.
  • the HBM gene or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location.
  • Vectors for introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector may be used.
  • Methods for introducing DNA into cells such as electroporation, calcium phosphate co-precipitation, and viral transduction are known in the art, and the choice of method is within the competence of one skilled in the art ( Robbins, Ed., Gene Therapy Protocols, Human Press, NJ (1997 )).
  • Cells transformed with the HBM. gene can be used as model systems to study osteoporosis and drug treatments that promote bone growth.
  • the HBM gene or fragment may be used in the manufacture of medicaments for use in gene therapy methods in order to increase the amount of the expression products of such genes in mesenchymal stem cells. It may be useful also to increase the level of expression of a given HBM protein, or a fragment thereof, even in those cells in which the wild type gene is expressed normally. Gene therapy would be carried out according to generally accepted methods as described by, for example, Friedman, Therapy for Genetic Diseases, Friedman, Ed., Oxford University Press, pages 105-121 (1991 ).
  • a virus or plasmid vector containing a copy of the HBM gene linked to expression control elements and capable of replicating inside mesenchymal stem cells is prepared.
  • Suitable vectors are known and described, for example, in U.S. Patent No. 5,252,479 and WO 93/07282 , the disclosures of which are incorporated by reference herein in their entirety.
  • the vector is then injected into the patient, either locally into the bone marrow or systemically (in order to reach any mesenchymal stem cells located at other sites, i.e., in the blood). If the transfected gene is not permanently incorporated into the genome of each of the targeted cells, the treatment may have to be repeated periodically.
  • Gene transfer systems known in the art may be useful in the practice of the medicaments for gene therapy of the present invention. These include viral and non-viral transfer methods.
  • viruses have been used as gene transfer vectors, including polyoma, i.e., SV40 ( Madzak et al, J. Gen. Virol., 73:1533-1536 (1992 )), adenovirus ( Berkner, Curr. Top. Microbiol. Immunol., 158:39-61 (1992 ); Berkner et al, Bio Techniques, 6:616-629 (1988 ); Gorziglia et al, J. Virol., 66:4407-4412 (1992 ); Quantin et al, Proc. Natl.
  • Non-viral gene transfer methods known in the art include chemical techniques such as calcium phosphate coprecipitation ( Graham et al, Virology, 52:456-467 (1973 ); Pellicer et al, Science, 209:1414-1422 (1980 )), mechanical techniques, for example microinjection ( Anderson et al, Proc. Natl. Acad. Sci. USA, 77:5399-5403 (1980 ); Gordon et al, Proc. Natl. Acad. Sci.
  • Viral-mediated gene transfer can be combined with direct in vivo vectors to the mesenchymal stem cells and not into the surrounding cells ( Romano et al, In Vivo, 12(1):59-67 (1998 ); Gonez et al, Hum. Mol. Genetics, 7(12):1913-9 (1998 )).
  • the retroviral vector producer cell line can be injected into the bone marrow ( Culver et al, Science, 256:1550-1552 (1992 )). Injection of producer cells would then provide a continuous source of vector particles. This technique has been approved for use in humans with inoperable brain tumors.
  • plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein, and the resulting complex is bound to an adenovirus vector.
  • the trimolecular complex is then used to infect cells.
  • the adenovirus vector permits efficient binding, internalization, and degradation of the endosome before the coupled DNA is damaged.
  • Liposome/DNA complexes have been shown to be capable of mediating direct in vivo gene transfer. While in standard liposome preparations the gene transfer process is non-specific, localized in vivo uptake and expression have been reported in tumor deposits, for example, following direct in situ administration ( Nabel, Hum. Gene Ther., 3:399-410 (1992 )).
  • Cells and non-human animals that carry the HBM gene can be used as model systems to study and test for substances that have potential as therapeutic agents ( Onyia et al, J. Bone Miner. Res., 13:20-30 (1998 ); Broder et al, Bone, 21:225-235 (1997 )).
  • the cells are typically cultured mesenchymal stem cells. These may be isolated from individuals with somatic or germline HBM genes. Alternatively, the cell line can be engineered to carry the HBM gene, as described above. After a test substance is applied to the cells, the transformed phenotype of the cell is determined.
  • Any trait of transformed cells can be assessed, including formation of bone matrix in culture ( Broder et al, Bone, 21:225-235 (1997 )), mechanical properties ( Kizer et al, Proc. Natl. Acad. Sci. USA, 94:1013-1018 (1997 )), and response to application of putative therapeutic agents.
  • Non-human animals for testing therapeutic agents can be selected after treatment of germline cells or zygotes. Such treatments include insertion of the Zmax1 gene, as well as insertion of the HBM gene and disrupted homologous genes. Alternatively, the inserted Zmax1 gene(s) and/or HBM gene(s) of the non-human animals may be disrupted by insertion or deletion mutation of other genetic alterations using conventional techniques, such as those described by, for example, Capechi, Science, 244:1288 (1989 ); Valancuis et al, Mol.
  • the HBM gene causes this phenotype by altering the activities, levels, expression patterns, and modification states of other molecules involved in bone development.
  • molecules preferably proteins or mRNAs, whose activities, levels, expression patterns, and modification states are different between systems containing the Zmax 1 gene and systems containing the HBM gene.
  • Such systems can be, for example, cell-free extracts, cells, tissues or living organisms, such as mice or humans.
  • a mutant form of Zmax1 a complete deletion of Zmax1, mutations lacking the extracellular or intracellular portion of the protein, or any other mutation in the Zmax1 gene may be used.
  • antisense Zmax1 RNA or oligonucleotides it is also possible to use expression of antisense Zmax1 RNA or oligonucleotides to inhibit production of the Zmax1 protein.
  • a mutant form of HBM a complete deletion of HBM, mutations lacking the extracellular or intracellular portion of the HBM protein, or any other mutation in the HBM gene may be used.
  • antisense HBM RNA or ' oligonucleotides to inhibit production of the HBM protein.
  • Molecules identified by comparison of Zmax1 systems and HBM systems can be used as surrogate markers in pharmaceutical development or in diagnosis of human or animal bone disease. Alternatively, such molecules may be used in treatment of bone disease. See , Schena et al, Science, 270:467-470 (1995 ).
  • a transgenic mouse carrying the HBM gene in the mouse homologue is constructed.
  • a mouse of the genotype HBM/+ is viable, healthy and has elevated bone mass.
  • HBM/+ i.e., heterozygous
  • isogenic +/+ i.e., wild-type mice are sacrificed.
  • Bone tissue mRNA is extracted from each animal, and a "gene chip" corresponding to mRNAs expressed in the +/+ individual is constructed.
  • mRNA from different tissues is isolated from animals of each genotype, reverse-transcribed, fluorescently labeled, and then hybridized to gene fragments affixed to a solid support.
  • the ratio of fluorescent intensity between the two populations is indicative of the relative abundance of the specific mRNAs in the +/+ and HBM/+ animals.
  • Genes encoding mRNAs over- and under-expressed relative to the wild-type control are candidates for genes coordinately regulated by the HBM gene.
  • One standard procedure for identification of new proteins that are part of the same signaling cascade as an already-discovered protein is as follows. Cells are treated with radioactive phosphorous, and the already-discovered protein is manipulated to be more ore less active. The phosphorylation state of other proteins in the cell is then monitored by polyacrylamide gel electrophoresis and autoradiography, or similar techniques.
  • Levels of activity of the known protein may be manipulated by many methods, including, for example, comparing wild-type mutant proteins using specific inhibitors such as drugs or antibodies, simply adding or not adding a known extracellular protein, or using antisense inhibition of the expression of the known protein ( Tamura et al, Science, 280(5369):1614-7 (1998 ); Meng, EMBO J., 17(15):4391-403 (1998 ); Cooper et al, Cell, 1:263-73 (1982 )).
  • proteins with different levels of phosphorylation are identified in TE85 osteosarcoma cells expressing either a sense or antisense cDNA for Zmax1.
  • TE85 cells normally express high levels of Zmax1 ( Dong et al, Biochem. & Biophys. Res. Comm., 251:784-790 (1998 )).
  • Cells containing the sense construct express even higher levels of Zmax1, while cells expressing the antisense construct express lower levels.
  • unlabeled proteins may be separated by SDS-PAGE and subjected to immunoblotting, using the commercially available anti-phosphotyrosine antibody as a probe ( Thomas et al, Nature, 376(6537):267-71 (1995 )).
  • antisense RNA transfection with chemically modified antisense oligonucleotides can be used ( Woolf et al, Nucleic Acids Res., 18(7):1763-9 (1990 )).
  • markers for bone development and mineralization can be useful in developing treatments for bone disorders, and for diagnosing patients who may be at risk for later development of bone disorders.
  • markers are N- and C-terminal telopeptide markers described, for example, in U.S. Patent Nos. 5,455,179 , 5,641,837 and 5,652,112 , the disclosures of which are incorporated by reference herein in their entirety.
  • CD4 counts and viral load are useful surrogate markers for disease progression ( Vlahov et al, JAMA, 279(1):35-40 (1998 )).
  • a surrogate marker can be any characteristic that is easily tested and relatively insensitive to non-specific influences.
  • a surrogate marker can be a molecule such as a protein or mRNA in a tissue or in blood serum.
  • a surrogate marker may be a diagnostic sign such as sensitivity to pain, a reflex response or the like.
  • surrogate markers for elevated bone mass are identified using a pedigree of humans carrying the HBM gene.
  • Blood samples are withdrawn from three individuals that carry the HBM gene, and from three closely related individuals that do not. Proteins in the serum from these individuals are electrophoresed on a two dimensional gel system, in which one dimension separates proteins by size, and another dimension separates proteins by isoelectric point ( Epstein et al, Electrophoresis, 17(11):1655-70 (1996 )). Spots corresponding to proteins are identified. A few spots are expected to be present in different amounts or in slightly different positions for the HBM individuals compared to their normal relatives. These spots correspond to proteins that are candidate surrogate markers.
  • the identities of the proteins are determined by microsequencing, and antibodies to the proteins can be produced by standard methods for use in diagnostic testing procedures.
  • Diagnostic assays for HBM proteins or other candidate surrogate markers include using antibodies described in this invention and a reporter molecule to detect HBM in human body fluids, membranes, bones, cells, tissues or extracts thereof.
  • the antibodies can be labeled by joining them covalently or noncovalently with a substance that provides a detectable signal.
  • reporter molecules or labels are described including radionuclides, enzymes, fluorescent, chemi-luminescent or chromogenic agents ( U.S. Patent Nos. 3,817,837 ; 3,850,752 ; 3,939,350 ; 3,996,345 ; 4,277,437 ; 4,275,149 ; and 4,366,241 ).
  • the levels of candidate surrogate markers are measured in normal individuals and in patients suffering from a bone disorder, such as osteoporosis, osteoporosis pseudoglioma, Engelmann's disease, Ribbing's disease, hyperphosphatasemia, Van Buchem's disease, melorheostosis, osteopetrosis, pychodysostosis, sclerosteosis, osteopoikilosis, acromegaly, Paget's disease, fibrous dysplasia, tubular stenosis, osteogenesis imperfecta, hypoparathyroidism, pseudohypoparathyroidism, pseudopseudohypoparathyroidism, primary and secondary hyperparathyroidism and associated syndromes, hypercalciuria, medullary carcinoma of the thyroid gland, osteomalacia and other diseases.
  • Techniques for measuring levels of protein in serum in a clinical setting using antibodies are well established. A protein that is consistently present in higher or lower levels in individuals carrying a particular disease or type
  • a surrogate marker can be used in diagnosis of a bone disorder. For example, consider a child that present to a physician with a high frequency of bone fracture. The underlying cause may be child abuse, inappropriate behavior by the child, or a bone disorder. To rapidly test for a bone disorder, the levels of the surrogate marker protein are measured using the antibody described above.
  • HBM-inducible mRNA set a set of bone mRNAs, termed the "HBM-inducible mRNA set" is found to be overexpressed in HBM/+ mice as compared to +/+ mice, as described above. Expression of this set can be used as a surrogate marker. Specifically, if treatment of +/+ mice with a compound results in overexpression of the HBM-inducible mRNA set, then that compound is considered a promising candidate for further development.
  • This invention is particularly useful for screening compounds by using the Zmax1 or HBM protein or binding fragment thereof in any of a variety of drug screening techniques.
  • the Zmax1 or HBM protein or fragment employed in such a test may either be free in solution, affixed to a solid support, or borne on a cell surface.
  • One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the protein or fragment, preferably in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays.
  • One may measure, for example, for the formation of complexes between a Zmax1 or HBM protein or fragment and the agent being tested, or examine the degree to which the formation of a complex between a Zmax1 or HBM protein or fragment and a known ligand is interfered with by the agent being tested.
  • the present invention provides methods of screening for drugs comprising contacting such an agent with a HBM protein or fragment thereof and assaying (i) for the presence of a complex between the agent and the HBM protein or fragment, or (ii) for the presence of a complex between the HBM protein or fragment and a ligand, by methods well known in the art.
  • the HBM protein or fragment is typically labeled. Free HBM protein or fragment is separated from that present in a protein:protein complex, and the amount of free (i.e., uncomplexed) label is a measure of the binding of the agent being tested to HBM or its interference with HBM: ligand binding, respectively.
  • Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the Zmax1 or HBM proteins and is described in detail in WO 84/03564 .
  • large numbers of different small-peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface.
  • the peptide test compounds are reacted with Zmax1 or HBM proteins and washed.
  • Bound Zmax1 or HBM protein is then detected by methods well known in the art.
  • Purified Zmax1 or HBM can be coated directly onto plates for use in the aforementioned drug screening techniques.
  • non-neutralizing antibodies to the protein can be used to capture antibodies to immobilize the Zmax1 or HBM protein on the solid phase.
  • This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of specifically binding the HBM protein compete with a test compound for binding to the HBM protein or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants of the HBM protein.
  • a further technique for drug screening involves the use of host eukaryotic cell lines or cells (such as described above) that have a nonfunctional Zmax1 or HBM gene. These host cell lines or cells are defective at the Zmax1 or HBM protein level. The host cell lines or cells are grown in the presence of drug compound. The rate of growth of the host cells is measured to determine if the compound is capable of regulating the growth of Zmax1 or HBM defective cells.
  • the goal of rational drug design is to produce structural analogs of biologically active proteins of interest or of small molecules with which they interact (e.g., agonists, antagonists, inhibitors) in order to fashion drugs which are, for example, more active or stable forms of the protein, or which, e.g., enhance or interfere with the function of a protein in vivo. See, e.g., Hodgson, BiolTechnology, 9:19-21 (1991 ).
  • one first determines the three-dimensional structure of a protein of interest (e.g., Zmax1 or HBM protein) or, for example, of the Zmax1- or HBM-receptor or ligand complex, by x-ray crystallography, by computer modeling or most typically, by a combination of approaches. Less often, useful information regarding the structure of a protein may be gained by modeling based on the structure of homologous proteins.
  • a protein of interest e.g., Zmax1 or HBM protein
  • peptides e.g., Zmax1 or HBM protein
  • alanine scan Wells, Methods in Enzymol., 202: 390-411 (1991 )
  • an amino acid residue is replaced by Ala, and its effect on the peptide's activity is determined.
  • Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.
  • drugs which have, e.g., improved Zmax1 or HBM protein activity or stability or which act as inhibitors, agonists, antagonists, etc. of Zmax1 or HBM protein activity.
  • sufficient amounts of the Zmax1 or HBM protein may be made available to perform such analytical studies as x-ray crystallography.
  • the knowledge of the Zmax1 or HBM protein sequence provided herein will guide those employing computer modeling techniques in place of, or in addition to x-ray crystallography.
  • the HBM DNA and HBM protein can be used for vertebrate and preferably human therapeutic agents and for avian and mammalian veterinary agents, including for livestock breeding.
  • Birds including, for example, chickens, roosters, hens, turkeys, ostriches, ducks, pheasants and quails, can benefit from the identification of the gene and pathway for high bone mass.
  • weakened bones due to husbandry conditions cause cage layer fatigue, osteoporosis and high mortality rates.
  • Additional therapeutic agents to treat osteoporosis or other bone disorders in birds can have considerable beneficial effects on avian welfare and the economic conditions of the livestock industry, including, for example, meat and egg production.
  • specific oligonucleotides may be constructed and used to assess the level of Zmax1 mRNA or HBM mRNA, respectively, in bone tissue or in another tissue that affects bone development.
  • polymerase chain reaction can be used to test whether a person has the HBM gene, which affects bone density.
  • Two oligonucleotides are synthesized by standard methods or are obtained from a commercial supplier of custom-made oligonucleotides. The length and base composition are determined by standard criteria using the Oligo 4.0 primer Picking program (Wojchich Rychlik, 1992).
  • One of the oligonucleotides is designed so that it will hybridize only to HBM DNA under the PCR conditions used.
  • the other oligonucleotide is designed to hybridize a segment of Zmax1 genomic DNA such that amplification of DNA using these oligonucleotide primers produces a conveniently identified DNA fragment.
  • the pair of primers CCAAGTTCTGAGAAGTCC (SEQ ID NO:32) and AATACCTGAAACCATACCTG (SEQ ID NO:33) will amplify a 530 base pair DNA fragment from a DNA sample when the following conditions are used: step 1 at 95°C for 120 seconds; step 2 at 95°C for 30 seconds; step 3 at 58°C for 30 seconds; step 4 at 72°C for 120 seconds; where steps 2-4 are repeated 35 times.
  • Tissue samples may be obtained from hair follicles, whole blood, or the buccal cavity.
  • the fragment generated by the above procedure is sequenced by standard techniques. Individuals heterozygous for the HBM gene will show an equal amount of G and T at the second position in the codon for glycine 171. Normal or homozygous wild-type individuals will show only G at this position.
  • Other amplification techniques besides PCR may be used as alternatives, such as ligation-mediated PCR or techniques involving Q-beta replicase ( Cahill et al, Clin. Chem., 37(9):1482-5 (1991 )).
  • the oligonucleotides AGCTGCTCGT AGCTG TCTCTCCCTGGATCACGGGTACATGTACTGGACAGACTGGGT (SEQ ID NO:34) and TGAGACGCCCCGGATTGAGCGGGCAGGGATAGCTTA TTCCCTGTGCCGCATTACGGC (SEQ ID NO:35) can be hybridized to a denatured human DNA sample, treated with a DNA ligase, and then subjected to PCR amplification using the primer oligonucleotides AGCTGCTCGTAGCTGTCT CTCCCTGGA (SEQ ID NO:36) and GCCGTAATGCGGCACAGGGAATAAGCT (SEQ ID NO:37).
  • the outer 27 bases are random sequence corresponding to primer binding sites, and the inner 30 bases correspond to sequences in the Zmax1 gene.
  • the T at the end of the first oligonucleotide corresponds to the HBM gene.
  • the first two oligonucleotides are ligated only when hybridized to human DNA carrying the HBM gene, which results in the formation of an amplifiable 114 bp DNA fragment.
  • Products of amplification can be detected by agarose gel electrophoresis, quantitative hybridization, or equivalent techniques for nucleic acid detection known to one skilled in the art of molecular biology ( Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring, NY (1989 )).
  • alterations in the Zmax1 gene or the HBM gene may be diagnosed by the same type of amplification-detection procedures, by using oligonucleotides designed to identify those alterations. These procedures can be used in animals as well as humans to identify alterations in Zmax1 or HBM that affect bone development.
  • Expression of Zmax1 or HBM in bone tissue may be accomplished by fusing the cDNA of Zmax1 or HBM, respectively, to a bone-specific promoter in the context of a vector for genetically engineering vertebrate cells.
  • DNA constructs are introduced into cells by packaging the DNA into virus capsids, by the use of cationic liposomes, electroporation, or by calcium phosphate transfection.
  • Transfected cells preferably osteoblasts, may be studied in culture or may be introduced into bone tissue in animals by direct injection into bone or by intravenous injection of osteoblasts, followed by incorporation into bone tissue ( Ko et al, Cancer Research, 56(20):4614-9 (1996 )).
  • the osteocalcin promoter which is specifically active in osteoblasts, may be used to direct transcription of the Zmax1 gene or the HBM gene.
  • Any of several vectors and transfection methods may be used, such as retroviral vectors, adenovirus vectors, or vectors that are maintained after transfection using cationic liposomes, or other methods and vectors described herein.
  • Alteration of the level of functional Zmax1 protein or HBM protein affects the level of bone mineralization.
  • levels of functional Zmax1 protein or HBM protein By manipulating levels of functional Zmax1 protein or HBM protein, it is possible to affect bone development and to increase or decrease levels of bone mineralization. For example, it may be useful to increase bone mineralization in patients with osteoporosis. Alternatively, it may be useful to decrease bone mineralization in patients with osteopetrosis or Paget's disease.
  • Alteration of Zmax1 levels or HBM levels can also be used as a research tool. Specifically, it is possible to identify proteins, mRNA and other molecules whose level or modification status is altered in response to changes in functional levels of Zmax1 or HBM. The pathology and pathogenesis of bone disorders is known and described, for example, in Rubin and Farber (Eds.), Pathology, 2nd Ed., S.B. Lippincott Co., Philadelphia, PA (1994 ).
  • Zmax1 or HBM A variety of techniques can be used to alter the levels of functional Zmax1 or HBM. For example, intravenous or intraosseous injection of the extracellular portion of Zmax1 or mutations thereof, or HBM or mutations thereof, will alter the level of Zmax1 activity or HBM activity, respectively, in the body of the treated human, animal or bird. Truncated versions of the Zmax1 protein or HBM protein can also be injected to alter the levels of functional Zmax1 protein or HBM protein, respectively. Certain forms of Zmax1 or HBM enhance the activity of endogenous protein, while other forms are inhibitory.
  • the HBM protein is used to treat osteoporosis.
  • the extracellular portion of the HBM protein is used.
  • This HBM protein may be optionally modified by the addition of a moiety that causes the protein to adhere to the surface of cells.
  • the protein is prepared in a pharmaceutically acceptable solution and is administered by injection or another method that achieves acceptable pharmacokinetics and distribution.
  • Zmax1 or HBM levels are increased or decreased by gene therapy techniques.
  • osteoblasts or another useful cell type are genetically engineered to express high levels of Zmax1 or HBM as described above.
  • antisense constructs that specifically reduce the level of translatable Zmax1 or HBM mRNA can be used.
  • a tissue-nonspecific promoter may be used, such as the CMV promoter or another commercially available promoter found in expression vectors ( Wu et al, Toxicol. Appl. Pharmacol., 141(1):330-9 (1996 )).
  • a Zmax1 cDNA or its antisense is transcribed by a bone-specific promoter, such as the osteocalcin or another promoter, to achieve specific expression in bone tissue.
  • a bone-specific promoter such as the osteocalcin or another promoter
  • antibodies against Zmax1 or HBM are used to inhibit its function. Such antibodies are identified herein.
  • drugs that inhibit Zmax1 function or HBM function are used.
  • Such drugs are described herein and optimized according to techniques of medicinal chemistry well known to one skilled in the art of pharmaceutical development.
  • Zmax1 and HBM interact with several proteins, such as ApoE.
  • Molecules that inhibit the interaction between Zmax1 or HBM and ApoE or another binding partner are expected to alter bone development and mineralization.
  • Such inhibitors may be useful as drugs in the treatment of osteoporosis, osteopetrosis, or other diseases of bone mineralization.
  • Such inhibitors may be low molecular weight compounds, proteins or other types of molecules. See, Kim et al, J. Biochem. (Tokyo), 124(6):1072-1076 (1998 ).
  • Inhibitors of the interaction between Zmax1 or HBM and interacting proteins may be isolated by standard drug-screening techniques.
  • Zmax1 protein, (or a fragment thereof) or HBM protein (or a fragment thereof) can be immobilized on a solid support such as the base of microtiter well.
  • a second protein or protein fragment, such as ApoE is derivatized to aid in detection, for example with fluorescein.
  • Iodine, or biotin then added to the Zmax1 or HBM in the presence of candidate compounds that may specifically inhibit this protein-protein domain of Zmax1 or HBM, respectively, and thus avoid problems associated with its transmembrane segment.
  • Drug screens of this type are well known to one skilled in the art of pharmaceutical development.
  • binding proteins can be identified by standard methods, such as coimmunoprecipitation, co-fractionation, or the two-hybrid screen ( Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons (1997 )).
  • the extracellular domain of Zmax1 or HBM is fused to LexA and expressed for the yeast vector pEG202 (the "bait") and expressed in the yeast strain EGY48.
  • the yeast strain is transformed with a "prey" library in the appropriate vector, which encodes a galactose-inducible transcription-activation sequence fused to candidate interacting proteins.
  • a "prey” library in the appropriate vector, which encodes a galactose-inducible transcription-activation sequence fused to candidate interacting proteins.
  • proteins that interact with HBM, but not Zmax1 are identified using a variation of the above procedure ( Xu et al, Proc. Natl. Acad. Sci. USA, 94(23):12473-8 (Nov. 1997 )).
  • This variation of the two-hybrid system uses two baits, and Zmax1 and HBM are each fused to LexA and TetR, respectively.
  • proteins that interact with the HBM but not Zmax1 are also isolated.
  • Zmax1 or HBM interacting proteins As an alternative method of isolating Zmax1 or HBM interacting proteins, a biochemical approach is used.
  • the Zmax1 protein or a fragment thereof, such as the extracellular domain, or the HBM protein or a fragment thereof, such as the extracellular domain, is chemically coupled to Sepharose beads.
  • the Zmax1- or HBM-coupled beads are poured into a column.
  • Sepharose beads used for coupling proteins and the methods for performing the coupling are commercially available (Sigma), and the procedures described here are well known to one skilled in the art of protein biochemistry.
  • proteins that are eluted by high salt from the Zmax1- or HBM-Sepharose column are then added to an HBM-Zmax1-sepharose column. Proteins that flow through without sticking are proteins that bind to Zmax1 but not to HBM. Alternatively, proteins that bind to the HBM protein and not to the Zmax1 protein can be isolated by reversing the order in which the columns are used.
  • the plasmid containing the two "hooks” is linearized with a restriction endonuclease or is produced by another method such as PCR.
  • This linear DNA fragment is introduced into yeast cells along with human genomic DNA.
  • yeast Saccharomyces cerevisiae is used as a host cell, although Larionov et al (in press) have reported using chicken host cells as well.
  • the endogenous host cell converts the linear plasmid to a circle by a recombination event whereby the region of the human genomic DNA homologous to the "hooks" is inserted into the plasmid.
  • This plasmid can be recovered and analyzed by methods well known to one skilled in the art. Obviously, the specificity for this reaction requires the host cell machinery to recognize sequences similar to the "hooks" present in the linear fragment. However, 100% sequence identity is not required, as shown by Kouprina et al, Genomic, 53(1):21-28 (October 1998 ), where the author describes using degenerate repeated sequences common in the human genome to recover fragments of human DNA from a rodent/human hybrid cell line.
  • radial TAR cloning the other region of sequence similarity to drive the recombination is derived from a repeated sequence from the genome. In this way, regions of DNA adjacent to the Zmax1 gene coding region can be recovered and examined for alterations that may affect function.
  • polymorphic genetic markers linked to the HBM gene or to Zmax1 is very useful in predicting susceptibility to osteoporosis or other bone diseases.
  • Koller et al, Amer. J. Bone Min. Res., 13:1903-1908 (1998 ) have demonstrated that the use of polymorphic genetic markers is useful for linkage analysis.
  • the identification of polymorphic genetic markers within the high bone mass gene will allow the identification of specific allelic variants that are in linkage disequilibrium with other genetic lesions that affect bone development.
  • the over-expression or repression of Zmax1 activity permits the identification of molecules that are directly regulated by the Zmax1 gene.
  • These genes are potential targets for therapeutics aimed at modulating tissue calcification.
  • an animal such as the LDLR -/-, mouse is fed a high fat diet and is observed to demonstrate expression of markers of tissue calcification, including Zmax1.
  • These animals are then treated with antibodies to Zmax1 or HBM protein, antisense oligonucleotides directed against Zmax1 or HBM cDNA, or with compounds known to bind the Zmax1 or HBM protein or its binding partner or ligand.
  • RNA or proteins are extracted from the vascular tissue and the relative expression levels of the genes expressed in the tissue are determined by methods well known in the art. Genes that are regulated in the tissue are potential therapeutic targets for pharmaceutical development as modulators of tissue calcification.
  • nucleic acids, proteins, peptides, amino acids, small molecules or other pharmaceutically useful compounds of the present invention may be administered in the form of a composition with a pharmaceutically acceptable carrier, excipient or diluent, which are well known in the art.
  • the individual may be a mammal or a bird, preferably a human, a rat, a mouse or bird.
  • Such compositions may be administered to an individual in a pharmaceutically effective amount. The amount administered will vary depending on the condition being treated and the patient being treated.
  • the compositions may be administered alone or in combination with other treatments.
  • the propositus was referred by her physicians to the Creighton Osteoporosis Center for evaluation of what appeared to be unusually dense bones. She was 18 years old and came to medical attention two years previous because of back pain, which was precipitated by an auto accident in which the car in which she was riding as a passenger was struck from behind. Her only injury was soft tissue injury to her lower back that was manifested by pain and muscle tenderness. There was no evidence of fracture or subluxation on radiographs. The pain lasted for two years, although she was able to attend school full time. By the time she was seen in the Center, the pain was nearly resolved and she was back to her usual activities as a high school student. Physical exam revealed a normal healthy young woman standing 66 inches and weighing 128 pounds.
  • Radiographs of the entire skeleton revealed dense looking bones with thick cortices. All bones of the skeleton were involved. Most importantly, the shapes of all the bones were entirely normal.
  • the spinal BMC was 94.48 grams in L1-4, and the spinal BMD was 1.667 gm/cm 2 in L1-4. BMD was 5.62 standard deviations (SD) above peak skeletal mass for women. These were measured by DXA using a Hologic 2000 ⁇ . Her mother was then scanned and a lumbar spinal BMC of 58.05 grams and BMD of 1.500 gm/cm 2 were found. Her mother's values place her 4.12 SD above peak mass and 4.98 SD above her peers. Her mother was 51 years old, stood 65 inches and weighed 140 pounds.
  • the present invention describes DNA sequences derived from two BAC clones from the HBM gene region, as evident in Table 7 below, which is an assembly of these clones.
  • Clone b200e21-h (ATCC No. 980812; SEQ ID NOS: 10-11) was deposited at the American Type Culture Collection (ATCC), 10801 University Boulevard., Manassas, VA 20110-2209 U.S.A., on December 30, 1997.
  • Clone b527d12-h (ATCC No. 980720; SEQ ID NOS: 5-9) was deposited at the American Type Culture Collection (ATCC), 10801 University Boulevard., Manassas, VA 20110-2209 U.S.A., on October 2, 1998.
  • sequences are unique reagents that can be used by one skilled in the art to identify DNA probes for the Zmax1 gene, PCR primers to amplify the gene, nucleotide polymorphisms in the Zmax1 gene, or regulatory elements of the Zmax1 gene. TABLE 7 Contig ATCC No. SEQ ID NO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)

Claims (30)

  1. Isolierte Nucleinsäuresequenz gemäß SEQ ID NO:2.
  2. Isolierte Nucleinsäuresequenz nach Anspruch 1, wobei es sich bei der Nucleinsäuresequenz um DNA handelt.
  3. Isolierte Aminosäuresequenz gemäß SEQ ID NO:4.
  4. Nucleinsäuresequenz, die für die Aminosäuresequenz von SEQ ID NO:4 kodiert.
  5. Replikativer Klonierungsvektor, umfassend die Nucleinsäuresequenz von Anspruch 1 und ein in einer isolierten Wirtszelle operatives Replikon.
  6. Isolierte Wirtszelle, die mit dem replikativen Klonierungsvektor von Anspruch 5 transformiert ist.
  7. Expressionsvektor, umfassend die Nucleinsäuresequenz von Anspruch 1 in funktioneller Verknüpfung mit einer regulatorischen Transkriptionsregion.
  8. Isolierte Wirtszelle, die mit dem Expressionsvektor von Anspruch 7 transformiert ist.
  9. In vitro-Verfahren zum Testen einer Substanz als therapeutisches Mittel zur Knochenmodulation in einem Wirt, umfassend die Verabreichung der Nucleinsäure von Anspruch 1 an eine Wirtszelle und die Feststellung, ob eine Knochenmodulation eintritt.
  10. Verfahren zum Identifizieren eines an der Knochenmodulation beteiligten Moleküls, umfassend das Identifizieren eines Moleküls, das an eine isolierte Aminosäuresequenz gemäß SEQ ID NO:4 oder an eine durch die Nucleinsäuresequenz von SEQ ID NO: 2 kodierte Aminosäuresequenz bindet, oder die Bindung eines Moleküls an eine isolierte Aminosäuresequenz gemäß SEQ ID NO:4 oder an eine durch die Nucleinsäuresequenz von SEQ ID NO:2 kodierte Aminosäuresequenz hemmt.
  11. Verfahren zum Identifizieren eines an der Knochenmodulation beteiligten Proteins, umfassend das Identifizieren eines Proteins, das einen Expressionsgrad aufweist, der in einem ersten Wirt, der das Zmaxl-Gen gemäß SEQ ID NO:1 umfasst, unterschiedlich ist im Vergleich zu einem zweiten Wirt, der eine Nucleinsäuresequenz gemäß SEQ ID NO:2 oder eine für die Aminosäuresequenz gemäß SEQ ID NO:4 kodierende Nucleinsäuresequenz umfasst.
  12. Verfahren zum Testen auf eine hohe Knochenmasseaktivität (HBM-Aktivität), umfassend das Immobilisieren eines HBM-Proteins gemäß SEQ ID NO:4, das Binden eines Proteins an das HBM-Protein und das Messen des Ausmaßes der Bindung.
  13. Verfahren zum Identifizieren eines als Kandidat in Frage kommenden Moleküls, das an der Knochenmodulation beteiligt ist, umfassend
    das Identifizieren eines Moleküls, das an die Nucleinsäuresequenz gemäß SEQ ID NO:1 bindet oder die Bindung eines Moleküls an die Nucleinsäuresequenz von SEQ ID NO:1 hemmt;
    das Identifizieren eines Moleküls, das an die Nucleinsäuresequenz gemäß SEQ ID NO:2 bindet oder die Bindung eines Moleküls an die Nucleinsäuresequenz gemäß SEQ ID NO:2 hemmt; und
    das Vergleichen des Ausmaßes der Bindung oder des Ausmaßes der Hemmung der Bindung des Moleküls an die jeweilige Nucleinsäuresequenz,
    wobei das Molekül, das mehr oder weniger an die Nucleinsäuresequenz gemäß SEQ ID NO:2 oder die Nucleinsäuresequenz gemäß SEQ ID NO:1 bindet oder die Bindung daran hemmt, das als Kandidat in Frage kommende Molekül darstellt.
  14. In vitro-Verfahren zur Entwicklung eines Arzneimittels zur Behandlung von Knochenentwicklungsstörungen, umfassend das Identifizieren eines Moleküls, das an die Aminosäuresequenz gemäß SEQ ID NO:4 bindet.
  15. In vitro-Verfahren zur Entwicklung eines Arzneimittels zur Behandlung von Knochenentwicklungsstörungen, wobei das Verfahren folgendes umfasst:
    das Konstruieren einer ersten Wirtszelle, die das Zmaxl-Gen gemäß SEQ ID NO:1 oder das Protein von SEQ ID NO:3 enthält;
    das Konstruieren einer zweiten Wirtszelle, die eine Nucleinsäure gemäß SEQ ID NO:2 oder ein für SEQ ID NO:4 kodierendes Protein enthält;
    das Analysieren einer Differenz zwischen der ersten Wirtszelle und der zweiten Wirtszelle; und
    das Identifizieren eines Moleküls, das bei Zugabe zur ersten Wirtszelle bewirkt, dass die erste Wirtszelle ein charakteristisches Merkmal der zweiten Wirtszelle aufweist.
  16. Verfahren zum diagnostischen Screening auf eine genetische Veranlagung für eine Knochenentwicklungsstörung, umfassend das Screening einer Probe eines Patienten mit einer Nucleinsäuresequenz von SEQ ID NO:2 oder einer Nucleinsäuresequenz, die für die Aminosäuresequenz von SEQ ID NO:4 kodiert.
  17. Diagnostischer Test für Knochenentwicklungsstörungen, umfassend einen Antikörper gegen eine Aminosäuresequenz gemäß SEQ ID NO:4 oder eine durch eine Nucleinsäure gemäß SEQ ID NO:2 kodierte Aminosäuresequenz.
  18. Isolierte Nucleinsäuresequenz, umfassend mindestens 15 zusammenhängende Nucleotide von SEQ ID NO:2, wobei die 15 zusammenhängenden Nucleotide die Position 582 von SEQ ID NO:2 umfassen.
  19. Isolierte Nucleinsäuresequenz, umfassend mindestens 15 zusammenhängende Nucleotide von SEQ ID NO:2, wobei die 15 zusammenhängenden Nucleotide die Position 582 von SEQ ID NO:2 umfassen und wobei die isolierte Nucleinsäuresequenz für eine Aminosäuresequenz kodiert, die ein Valin entsprechend dem Valin in Position 171 von SEQ ID NO:4 umfasst und wobei die Valin-Substitution mit einem Phänotyp von hoher Knochenmasse verbunden ist.
  20. Isoliertes Nucleinsäuresegment mit mindestens 15 zusammenhängenden Nucleotiden, umfassend eine polymorphe Stelle aus der Nucleinsäuresequenz von SEQ ID NO:2, wobei G in Position 582 durch T ersetzt ist, sowie hierzu komplementäre Sequenzen.
  21. Verfahren zum Identifizieren eines Moleküls, das an der Knochenmodulation beteiligt ist, umfassend das Identifizieren eines Moleküls, das an das HBM-Polypeptid gemäß SEQ ID NO:4 bindet.
  22. Isoliertes HBM (hohe Knochenmasse)-Polynucleotid, umfassend eine Nucleinsäure, ausgewählt aus der Gruppe, bestehend aus:
    (a) einer Nucleinsäure mit der Sequenz gemäß SEQ ID NO:2;
    (b) einer Nucleinsäure, die für ein Polypeptid gemäß SEQ ID NO:4 kodiert;
    (c) einer Nucleinsäure, die komplementär zu einer Nucleinsäure gemäß
    (a) oder (b) ist; und
    (d) einer Nucleinsäure, die mindestens 15 zusammenhängende Nucleotide umfasst, die die Position 582 von SEQ ID NO:2 umfassen, aus einem Polynucleotid gemäß (a), (b) oder (c);
    wobei das isolierte HBM-Polynucleotid für ein Protein oder ein Polypeptid kodiert, das bei Verabreichung an ein Subjekt die Knochenmasse moduliert.
  23. Isolierte Nucleinsäuresequenz, umfassend mindestens 15 zusammenhängende Nucleotide von SEQ ID NO:2, wobei die 15 zusammenhängenden Nucleotide Nucleotide umfassen, die für eine Aminosäuresubstitution in Position 171 von SEQ ID NO:4 kodieren, wobei die Substition mit einem Phänotyp von hoher Knochenmasse verbunden ist.
  24. Isoliertes HBM (hohe Knochenmasse)-Polynucleotid, umfassend eine Nucleinsäure, ausgewählt aus der Gruppe, bestehend aus:
    (a) einer Nucleinsäure mit der Sequenz gemäß SEQ ID NO:2;
    (b) einer Nucleinsäure, die für ein Polypeptid gemäß SEQ ID NO:4 kodiert;
    (c) einer Nucleinsäure, die komplementär zu einer Nucleinsäure gemäß
    (a) oder (b) ist; und
    (d) einer Nucleinsäure, die mindestens 15 zusammenhängende Nucleotide umfasst, die die Position 582 von SEQ ID NO:2 umfassen, aus einem Polynucleotid gemäß (a), (b) und (c).
  25. Verwendung eines Antikörpers, der an ein Polypeptid bindet, das durch eine Nucleinsäure gemäß einem der Ansprüche 18, 20, 22 oder 24 kodiert wird und an der fokalen Adhäsionsignalgebung beteiligt ist, zur Herstellung eines Arzneimittels zur Modulation der Knochendichte.
  26. Verwendung eines Antikörpers, der an ein Polypeptid bindet, das durch eine Nucleinsäure gemäß einem der Ansprüche 18, 20, 22 oder 24 kodiert wird und an der fokalen Adhäsionssignalgebung beteiligt ist, zur Herstellung eines Arzneimittels zur Behandlung von Knochenentwicklungsstörungen.
  27. Verwendung nach Anspruch 25 oder 26, wobei das Polypeptid die Sequenz gemäß SEQ ID NO:4 aufweist.
  28. Antikörper, der an ein Polypeptid bindet, das durch eine Nucleinsäure gemäß einem der Ansprüche 18, 20, 22 oder 24 kodiert wird und an der fokalen Adhäsionssignalgebung beteiligt ist, zur Modulation der Knochendichte.
  29. Antikörper, der an ein Polypeptid bindet, das durch eine Nucleinsäure gemäß einem der Ansprüche 18, 20, 22 oder 24 kodiert wird und an der fokalen Adhäsionssignalgebung beteiligt ist, zur Behandlung von Knochenentwicklungsstörungen.
  30. Antikörper nach Anspruch 28 oder 29, wobei das Polypeptid die Sequenz gemäß SEQ ID NO:4 aufweist.
EP00941578A 2000-04-05 2000-06-21 Das hohe knochenmasse gen auf 11q13.3 Expired - Lifetime EP1268775B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08006373A EP1964921A3 (de) 2000-04-05 2000-06-21 Das Gen für hohe Knochenmasse 11q13.3

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/543,771 US6780609B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 1.1q13.3
US09/544,398 US6770461B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 11q13.3
US543771 2000-04-05
US544398 2000-04-05
PCT/US2000/016951 WO2001077327A1 (en) 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08006373A Division EP1964921A3 (de) 2000-04-05 2000-06-21 Das Gen für hohe Knochenmasse 11q13.3

Publications (2)

Publication Number Publication Date
EP1268775A1 EP1268775A1 (de) 2003-01-02
EP1268775B1 true EP1268775B1 (de) 2008-11-19

Family

ID=27067425

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941578A Expired - Lifetime EP1268775B1 (de) 2000-04-05 2000-06-21 Das hohe knochenmasse gen auf 11q13.3

Country Status (11)

Country Link
EP (1) EP1268775B1 (de)
JP (1) JP2004515209A (de)
CN (1) CN1454256A (de)
AR (1) AR028316A1 (de)
AU (2) AU2000256269B2 (de)
BR (1) BR0017197A (de)
CA (1) CA2402410A1 (de)
IL (1) IL151904A0 (de)
MX (1) MXPA02009791A (de)
NZ (1) NZ521769A (de)
WO (1) WO2001077327A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359367T1 (de) 1997-04-15 2007-05-15 Wellcome Trust Ltd As Trustee Ldl-rezeptor
US7244577B2 (en) 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
EP1313753A4 (de) * 2000-08-18 2004-09-15 Proskelia Regulatorgene und für die diagnose und therapie der osteoporose brauchbares system
BR0209563A (pt) * 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
IL158750A0 (en) * 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
AU2003292404A1 (en) * 2002-12-13 2004-07-09 Oxagen Limited Genetic susceptibility
US20090276863A1 (en) * 2004-07-02 2009-11-05 Toshihiro Nakajima Protein formulations comprising s1-5
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
EP3339318A1 (de) * 2013-09-16 2018-06-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Mutiertes calreticulin zur diagnose von myeloidmalignitäten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7392696A (en) * 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
ATE359367T1 (de) * 1997-04-15 2007-05-15 Wellcome Trust Ltd As Trustee Ldl-rezeptor
BE1011331A6 (fr) * 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
JP2002506873A (ja) * 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
JP2002539843A (ja) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
NZ522600A (en) * 2000-05-26 2004-09-24 Genome Therapeutics Corp Regulating lipid levels via the Zmax1 or HBM gene
EP1313753A4 (de) * 2000-08-18 2004-09-15 Proskelia Regulatorgene und für die diagnose und therapie der osteoporose brauchbares system

Also Published As

Publication number Publication date
BR0017197A (pt) 2003-01-14
IL151904A0 (en) 2003-04-10
AU2000256269A1 (en) 2002-01-10
NZ521769A (en) 2004-12-24
MXPA02009791A (es) 2004-09-06
AU5626900A (en) 2001-10-23
WO2001077327A1 (en) 2001-10-18
AU2000256269B2 (en) 2006-11-02
EP1268775A1 (de) 2003-01-02
JP2004515209A (ja) 2004-05-27
CN1454256A (zh) 2003-11-05
CA2402410A1 (en) 2001-10-18
AR028316A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
US7416849B2 (en) HBM variants that modulate bone mass and lipid levels
US20090023905A1 (en) Transgenic animal model of bone mass modulation
JP4271735B2 (ja) 新規のｌｄｌ−レセプター
US20040170994A1 (en) DNA sequences for human tumour suppressor genes
AU2007200880A1 (en) Regulating lipid levels via the ZMAX1 or HBM gene
CA2433439A1 (en) Proteins and nucleic acids encoding same
EP1268775B1 (de) Das hohe knochenmasse gen auf 11q13.3
US7285400B2 (en) High bone mass gene of 11q13.3
US6225451B1 (en) Chromosome 11-linked coronary heart disease susceptibility gene CHD1
EP1964921A2 (de) Das Gen für hohe Knochenmasse 11q13.3
US6972176B2 (en) KVLQT1—a long QT syndrome gene
US20040221326A1 (en) Transgenic animal model of bone mass modulation
US20030219793A1 (en) High bone mass gene of 11q13.3
US7151161B1 (en) Human genes of chromosome 11q13.3
AU2001269712B2 (en) Regulating lipid levels via the ZMAXI or HBM gene
AU2007200352A1 (en) The high bone mass gene of 11q13.3
Carulli et al. Regulating Lipid Levels Via the ZMAX1 or HBM Gene
AU2001269712A2 (en) Regulating lipid levels via the ZMAXI or HBM gene
AU2001269712A1 (en) Regulating lipid levels via the ZMAXI or HBM gene
ALLEN et al. Patent 2446821 Summary
US20030064489A1 (en) Novel polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LITTLE, RANDALL, D.

Inventor name: RECKER, ROBERT, R.

Inventor name: JOHNSON, MARK, L.

Inventor name: CARULLI, JOHN, P.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CREIGHTON UNIVERSITY

Owner name: GENOME THERAPEUTICS CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 A

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/11 B

Ipc: 7A 61K 38/17 B

Ipc: 7A 61K 49/00 B

Ipc: 7C 07K 14/705 B

17Q First examination report despatched

Effective date: 20050301

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CREIGHTON UNIVERSITY

Owner name: OSCIENT PHARMACEUTICALS CORPORATION

17Q First examination report despatched

Effective date: 20050301

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CARULLI, JOHN, P.

Inventor name: LITTLE, RANDALL, D.

Inventor name: JOHNSON, MARK, L.

Inventor name: RECKER, ROBERT, R.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: THE HIGH BONE MASS GENE OF 11Q13.3

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: ANDRE ROLAND S.A.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60040870

Country of ref document: DE

Date of ref document: 20090102

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2316370

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090420

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090621

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20100101

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090621

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100101

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090622

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110629

Year of fee payment: 12

Ref country code: ES

Payment date: 20110628

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110628

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110625

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20110629

Year of fee payment: 12

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120621

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130228

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60040870

Country of ref document: DE

Effective date: 20130101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120702

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120621

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130101

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120622